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ABSTRACT 
 
Development of a “Self-Cleaning” Encapsulation Technology for Implantable Glucose 
Monitoring. (December 2009) 
Rebecca May Gant, B.S., Cornell University; 
M.E., Cornell University 
Co-Chairs of Advisory Committee: Dr. Gerard L. Coté 
  Dr. Melissa A. Grunlan  
 
The increasing prevalence of diabetes and the severity of long-term complications have 
emphasized the need for continuous glucose monitoring. Optically-based methods are 
advantageous as they have potential for noninvasive or minimally invasive detection.  
Fluorescence-based affinity assays, in particular, can be fast, reagentless, and highly 
specific. Poly(ethylene glycol) (PEG) microspheres have been used to encapsulate such 
fluorescently labeled molecules in a hydrogel matrix for implantation into the body. The 
matrix is designed to retain the sensing molecules while simultaneously allowing 
sufficient analyte diffusion. Sensing assays which depend upon a spatial displacement of 
molecules, however, experience limited motility and diminished sensor response in a 
dense matrix. In order to overcome this, a process of hydrogel microporation has been 
developed to create cavities within the PEG that contain the assay components in 
solution, providing improved motility for large sensing elements, while limiting leaching 
and increasing sensor lifetime. 
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For an implanted sensor to be successful in vivo, it should exhibit long-term stability and 
functionality. Even biocompatible materials that have no toxic effect on surrounding 
tissues elicit a host response. Over time, a fibrous capsule forms around the implant, 
slowing diffusion of the target analyte to the sensor and limiting optical signal 
propagation. To prevent this biofouling, a thermoresponsive nanocomposite hydrogel 
based on poly(N-isopropylacrylamide) was developed to create a self-cleaning sensor 
membrane. These hydrogels exist in a swollen state at temperatures below the volume 
phase transition temperature (VPTT) and become increasingly hydrophobic as the 
temperature is raised. Upon thermal cycling around the VPTT, these hydrogels exhibit 
significant cell release in vitro. However, the VPTT of the original formula was around 
33-34°C, resulting in a gel that is in a collapsed state, ultimately limiting glucose 
diffusion at body temperature. The hydrogel was modified by introducing a hydrophilic 
comonomer, N-vinylpyrrolidone (NVP), to raise the VPTT above body temperature. The 
new formulation was optimized with regard to diffusion, mechanical strength, and cell 
releasing capabilities under physiological conditions. Overall, this system is a promising 
method to translate a glucose-sensitive assay from the cuvette to the clinic for minimally 
invasive continuous glucose sensing. 
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CHAPTER I 
INTRODUCTION 
 
Motivation 
Glucose is a simple sugar and one of the most important fuels for the body. In order for 
the energy to get into cells though, a key is needed. This key is the hormone insulin. 
Diabetes mellitus is a disease in which the body does not produce or properly use 
insulin, leading to abnormal glucose levels. The term diabetes was first used by Araetus 
of Cappodocia (81 – 133 AD).1 The Greek word is comprised of dia, which means 
“through”, and betes, meaning “to go”.2 Combined the word was used to refer to the 
excessive amounts of urine that were passed by those affected by the disease. Mellitus, 
Latin for “honey”, was later added by Thomas Willis to describe the sweet taste of the 
urine of diabetics.  
 
In type 1 diabetes, which has previously been known as insulin-dependent (IDDM) or 
juvenile-onset, the immune system attacks the insulin-producing beta cells in the 
pancreas, resulting in little to no insulin production. In order to survive, type 1 diabetics 
must have daily insulin administrations either by injection or a pump. In type 2 diabetes, 
previously known as non-insulin dependent (NIDDM) or adult-onset, diabetics have 
developed an insulin resistance.3 As the cells do not use the insulin properly, the need for  
 
 
____________ 
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insulin rises, and the pancreas gradually loses its ability to produce the hormone. Type 2 
diabetes is often associated with obesity, older age, and family history and accounts for 
about 90 to 95% of diagnosed cases in adults.4 Gestational diabetes is similar to type 2 
diabetes in that it involves an inadequate level of insulin secretion and responsiveness, 
but it is first diagnosed during pregnancy. Though 90 to 95% of women revert to normal 
after pregnancy, maternal glucose levels must be controlled to avoid complications in 
both the mother and infant. In addition, women who have had gestational diabetes have a 
40 to 60% chance of developing diabetes in the following 5 to 10 years.4 
  
Incidence of Diabetes 
Diabetes is a debilitating disease that affects over 180 million people, according to the 
World Health Organization, with estimates projecting to 366 million in 2030.5,6 Figure 
1.1 shows the affected populations and future projections.7 In upper-middle income 
countries, diabetes-related deaths are expected to increase by over 80% between 2006 
and 2015.6 Even closer to home, the state of Texas experienced the second highest 
number of newly diagnosed cases (156,000) out of 33 states surveyed between 2005 and 
2007.8 The age-adjusted incidence of diabetes increased by 208% from the period of 
1995-1997 to 2005-2007. Overall, diabetes is rapidly becoming more prevalent, causing 
major concerns in the health care industry. 
 3
 
Figure 1.1. Prevalence of diabetes throughout the world in 2000 and projections for 2030 
 
 
The related costs in the United States alone, were estimated to be approximately $174 
billion in 2007.4 In addition to the costs incurred by known diabetics, approximately 5.7 
million people are undiagnosed.4  Furthermore, there are 57 million people in the U.S. 
with prediabetes that may develop into type 2 diabetes unless serious lifestyle 
interventions are performed to prevent or delay onset.9 Prediabetics can have impaired 
fasting glucose (IFG) in which the fasting blood sugar level is 100 to 125 mg/dL after an 
overnight fast and/or impaired glucose tolerance (IGT) where the blood sugar level is 
140 to 199 mg/dL after a 2 hour oral glucose tolerance test.4 The growing epidemic is so 
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serious that it prompted a United Nations Resolution on diabetes, which designates 
November 14th as World Diabetes Day in order to raise public awareness of the problem 
and encourages Member States to develop national policies for both the prevention and 
treatment of diabetes. 10,11 
 
Controlling Glucose Levels 
Better glycemic control can lead to better health and quality of life and is associated with 
a significant health care cost savings.12 While type 1 diabetes is typically treated with 
injections of insulin, type 2 diabetes is often controlled through diet, exercise, and oral 
medication. Figure 1.2 shows the breakdown of patients receiving insulin and/or oral 
medication.4 In order to administer either treatment, a diabetic must know how much 
glucose is in their blood. Typically, a finger is pricked with a small needle called a lancet 
to get a drop of blood which is then tested by an enzymatic assay in a glucometer 
machine.  
 
 
Figure 1.2. Treatment methods among adults with diagnosed diabetes in the United States, 
 2004-2006 
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Diabetes-related Complications 
Maintaining glucose levels in a tight range (70-120 mg/dL) may help avoid 
complications such as blindness, heart disease, stroke, kidney failure, and nerve 
damage.3,13 Adults with diabetes have about 2 to 4 times higher rates of death due to 
heart disease and 2 to 4 times higher risk of stroke.4 Diabetes is the leading cause of new 
cases of blindness among adults 20 to 74 years old.4 After only 15 years of diabetes, 
about 10% of people develop severe visual impairment.6 Diabetes is the primary cause 
of kidney failure, accounting for 44% of new cases in 2005, and 10 to 20% of diabetics 
die of kidney failure.4,6 Poorly controlled diabetes during pregnancy can cause major 
birth defects in 5 to 10% and spontaneous abortions in 15 to 20% of pregnancies.4 
Diabetic neuropathy causes about 60 to 70% of diabetics to have impaired sensation or 
pain in the feet and hands, slowed digestion of food in the stomach, carpal tunnel 
syndrome, erectile dysfunction, or other nerve problems.4 Diabetes is responsible for an 
amputation every 30 seconds and a death every 10 seconds.14 Regular monitoring of 
glucose levels is important for treating diabetes and minimizing the risk of such 
complications.13 
 
Commercially Available Sensors for SMBG 
While there are currently over 40 blood glucose meters that are commercially available 
for self-monitoring of blood glucose (SMBG), the majority of the market is shared 
between Roche Diagnostics, Johnson & Johnson’s LifeScan, Abbott, and Bayer.15 Most 
of these glucose sensors are based on an enzymatic assay that converts glucose in the 
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blood into a measurable end product, as proposed by Clark and Lyons in 1962.16 The 
most commonly used enzymes contain redox groups that change redox state during the 
biochemical reaction, such as glucose oxidase (GOx) and glucose dehydrogenase 
(GDH).15 For example, glucose oxidase can be fixed to an electrode where it will 
catalyze the conversion of glucose into gluconolactone and hydrogen peroxide. The 
hydrogen peroxide then reacts at the sensing electrode, resulting in a measurable electric 
current. 
glucose + O 
    
  gluconolactone + HO  
HO
          
  2e + O + 2H

 
 
Because the testing occurs ex vivo, results can be affected by environmental factors such 
as temperature, altitude, and humidity as well as internal confounders like hematocrit, 
uric acid, glutathione, and vitamin C.17 Additionally, the analytical quality of many self 
monitored tests does not meet American Diabetes Association error standards when 
performed by a patient as opposed to a trained technician.18 The ADA has stated that all 
SMBG systems should have a total error of less than 10%.18 The International 
Organization for Standardization more specifically specifies that a glucose meter should 
obtain 95% of results within 5, 10, and 15 mg/dL for glucose values less than 75 mg/dL 
and within 5%, 10%, 15%, and 20% of the reference if the glucose value is equal to or 
greater than 75 mg/dL.19  
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One of the main disadvantages of current SMBG meters is that they require a blood 
sample. Whether obtained through finger-pricking or forearm acquisition, this can be 
painful, cause calluses, and could lead to other complications such as infection. The 
inconvenience and embarrassment may also contribute to low patient compliance. 
Current guidelines regarding testing frequency vary depending on the individual patient 
treatment regimen. For example, the ADA recommends that patients using multiple 
insulin injections should test a minimum of three times a day.20 Cost may be another 
potentially prohibitive factor to testing. An individual disposable test strip is estimated to 
cost about $1, leading to an average annual expense of $1,460 for patients with type 1 
diabetes.21 This can be higher for patients using an insulin pump, who typically test more 
frequently.22 Another problem with the current SMBG meters is the potential for 
hypoglycemia unawareness. Testing is rarely done at night when patients are vulnerable 
to dangerous glucose levels while sleeping. Additionally, testing is done a few times a 
day at best, providing only a “snapshot” of the blood glucose level.23 
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CHAPTER II 
CONTINUOUS GLUCOSE SENSING 
 
Advantages of Continuous Glucose Sensing 
There are several advantages to continuous glucose monitoring that have driven research 
for the past 30+ years. It is estimated that a patient who closely monitors glucose levels 
will gain 5 more years of life, 5 more years of eyesight, 6 more years free of kidney 
disease, and 6 more years without amputations and nerve damage than the average 
patient.24 Increased SMBG is correlated with better long term glucose levels, but for 
practical reasons most patients do not test their blood sugar more than 5 to 7 times a 
day.25 Continuous glucose monitoring has been shown to help identify periods of 
significant glycemic excursion, which allowed physicians to modify recommendations 
for timing and dosage of insulin injections and dietary changes, resulting in improved 
glycemic control.26,27 In addition to lowering the average values of HbA1c, which is a 
form of hemoglobin used to quantify the average plasma glucose concentration over 
long periods of time, continuous monitoring has also been shown to reduce the rate of 
severe hypoglycemia, or dangerously low blood sugar.28 Alarms can also be 
incorporated into continuous glucose monitoring systems (CGMS) to warn patients 
when sugar levels exceed a certain range, preventing dangerous “highs” and “lows”, 
particularly at night when patients are unaware of their glycemic status. 
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In an effort to “close the loop” and develop an artificial pancreas system, current CGM 
systems have been paired with external insulin pumps. A recent clinical trial showed that 
insulin pump therapy combined with CGMS improves blood sugar levels more than 
conventional pump therapy.25 The idea of connecting glucose sensing to insulin delivery 
was first used in 1964 with intravenous infusions of insulin and glucose.29 A fully 
automated system could be achieved as shown in Figure 2.1, whereby the sensor detects 
the glucose concentration, relaying the information to a receiver that would determine 
the amount of insulin needed using a control algorithm. The information is then sent to 
the insulin infusion device which would distribute the appropriate amount of insulin to 
the body. This feedback-controlled system has the potential to eliminate the necessity of 
frequent patient performed blood draws and injections, while simultaneously improving 
glycemic control. 
 
 
 
Figure 2.1. Potential closed loop system for regulating in vivo glucose levels 
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Transdermal Meters 
Transdermal meters sample glucose through the intact skin by drawing the glucose out, 
typically using some sort of enhancement technique such as electric current 
(iontophoresis), acoustic energy (sonophoresis), chemicals that enhance the permeation 
of glucose through skin (passive diffusion), or mechanical permeation (microporation).30 
 
The first commercially available non-invasive glucose sensor in the US, the GlucoWatch 
Biographer (originally by Cygnus, Redwood City, CA), was approved by the FDA in 
2001 as an adjunct to traditional SMBG. The device extracts glucose using reverse 
iontophoresis. A low-level electric current is passed through the skin and uncharged 
glucose molecules are carried along by convective transport. The glucose concentration 
is then measured electrochemically using a glucose oxidation reaction. The system has 
shown good linearity between the recorded signal and blood glucose level, but has 
encountered many problems such as an average lag time behind blood glucose of 18 
minutes, low sensitivity in detecting hypoglycemic values below 3.9 mmol/L, and skin 
reactions at the electrode sites.31 Additionally, the GlucoWatch needs to warm up for 3 
hours and then makes only up to three measurement an hour for 12 hours before needing 
to be recalibrated via finger-stick.15 Animas purchased the technology in 2005 and 
attempted to make an improved 3rd generation GlucoWatch, but decided to cease sales of 
the device in 2007. 
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Impedance Measurements 
Another watch-type glucose sensing device, the Pendra, was introduced by the Swiss 
company Pendragon Medical in 2000 and received CE approval for use in Europe as a 
supplemental device to traditional SMBG in 2003.32 The Pendra determines glucose 
concentrations indirectly using impedance spectroscopy to measure sodium transport 
over the erythrocyte membrane, which is linked to changes in glucose. The sodium flux 
induces changes in impedance, which are detected and converted into a corresponding 
glucose value. Beyond normal physiological interference, impedance values can be 
influenced by additional confounders such as temperature, hematocrit, and erythrocyte 
sedimentation rate.33-35 Another drawback to this system is the lengthy calibration 
process that lasts 2 to 3 days, after which approximately 30% of patients are deemed 
ineligible to use the Pendra as their skin is found to be unsuitable for these 
measurements.32 During the calibration process, patients intentionally try to elevate 
glucose levels by at least 100 mg/dL to assess the signal sensitivity, which is contrary to 
normal glycemic goals.36 Furthermore, the adhesive tape must be changed daily followed 
by a 1 hour equilibration time and baseline adjustment before it can be used again.37,38 
Another prohibitive aspect is cost. The first devices were distributed for an initial €1,250 
followed by a leasing fee of €95 a month for at least two years.32 A postmarket reliability 
study found the results of Pendra-measured glucose to differ by 52% from traditional 
SMBG values. Additionally, 4.3% of the error was in a “danger zone” that would fail to 
detect severe hyperglycemia or hypoglycemia.39 A number of technical issues and 
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internal company concerns led Pendragon to cancel further marketing of the Pendra in 
2004 and the company eventually filed for bankruptcy in 2005.32 
 
Transcutaneous Monitors 
GlucoDay is a microdialysis device marketed in Europe by A. Menarini Diagnostics. 
Interstitial fluid is sampled through a subcutaneous catheter and the glucose 
concentration is detected using glucose oxidase. Calibration by finger-stick is required 
every 72 hours, but the current recommendations only allow the device to be worn for 48 
hours. Measurements are made every 3 minutes and the sensor has an excellent linear 
range extending to 27 mM (486 mg/dL), but the lag time of the sensor is about 35 
minutes.39-41 While patients reported experiencing little pain during catheter insertion, 
they expressed a mean discomfort of 3.6 out of 5 while wearing the device.42 In an age 
of increasingly smaller “nano” personal music devices, the GlucoDay is a bulky, 
Walkman-sized piece of machinery that is carried around in a pouch around the waist. 
Currently the catheter insertion is performed by a physician and the device is not 
approved for autonomous use.43 The device has the potential for real-time CGM, but as 
of yet, Menarini has not announced any plans to bring the GlucoDay to the U.S. market. 
 
There are currently four CGM systems available in the United States: the DexCom 
Seven, the FreeStyle Navigator, the Medtronic MiniMed Guardian REAL-Time System, 
and the Medtronic MiniMed Paradigm REAL-Time System, which is combined with a 
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manually operated insulin pump. These devices are transcutaneous and can remain in 
situ between three to seven days.44  
 
 
Table 2.1. Characteristics of commercially available CGMS 
Model Manufacturer Measurement 
Frequency 
Predictive 
Alarms 
Calibration Sensor 
Life 
Seven DexCom every 5 min No At 2 hr x 2, then 
every 12 hrs 
7 days 
Freestyle 
Navigator 
Abbott every 1 min Yes At 10, 12, 24, 72 
hr 
5 days 
Guardian Medtronic 
MiniMed 
every 5 min Yes At 2 h, 6 hr, then 
every 12 hrs 
72 hrs 
Paradigm Medtronic 
MiniMed 
every 5 min No At 2 h, 6 hr, then 
every 12 hrs 
72 hrs 
 
 
The subcutaneous portion of the sensor contains a glucose oxidase sensor that measures 
interstitial glucose in terms of electric current, continuously measuring glucose levels 
and sending readings via a wireless transmitter to a separate monitor. The data can be 
downloaded to a computer in the home or clinic and used to evaluate overall glycemic 
trends. The first generation of CGMS devices did not have a display for patient use, but 
were used only to provide information to physicians. The current systems generate real-
time measurements in the interstitial fluid, which can lag behind blood by up to 10-15 
minutes.45 This must be considered when a glycemic fluctuation is noticed and it is 
recommended that a finger-stick be performed prior to starting treatment such as an 
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insulin bolus. Additional finger-stick testing must be done to calibrate the systems upon 
initial setup and for recurring alignment as shown in Table 2.1.39 The overall percentage 
of error averages around 15% for each of these systems.46 Clinical studies concluded that 
the largest source of error is the calibration process.47 These CGM systems have shown a 
lot of promise in terms of helping patients to achieve tighter glycemic control and 
minimizing hypoglycemic events, but there is still much to be done to increase sensor 
longevity and overcome some of the other barriers mentioned here.26-28 
 
Optical Methods 
Optical glucose detection techniques are advantageous because they allow for the 
possibility of non-invasive or minimally-invasive sensing. A significant amount of 
research has been done as evidenced by the 3990 non-invasive/noninvasive glucose 
patents issued by the USPTO since 1976.48 A wide range of methods have been 
explored, including infrared absorption, near-infrared scattering, Raman spectroscopy, 
fluorescence spectroscopy, kromoscopy, thermal gradient spectroscopy, polarimetry, 
optoacoustic techniques, optothermal systems, and optical coherence tomography, but as 
of yet, none of these are commercially available.49,50 
 
One method to achieve continuous measurement is through the use of a fluorescence-
based glucose sensitive sensor that could be implanted intradermally. Once implanted, 
the corresponding optical signal would be monitored non-invasively with an external 
portable device. A system such as this would eliminate the potential for infection caused 
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by the transcutaneous nature of the current CGMS devices, while increasing accuracy 
over transdermal devices as the glucose concentration would be directly measured in the 
interstitial fluid. Fluorescence is the process by which a molecule in an excited state 
releases energy in the form of photons, as shown in Figure 2.2. Incoming light is 
absorbed by a fluorescent molecule in the ground state, S0, raising it to an excited energy 
state, S1. The molecule relaxes to a lower vibrational state through internal conversion 
(IC). Energy can then be released through spontaneous emission of a lower energy 
(longer wavelength) photon as in fluorescence, or through a nonradiative pathway such 
as quenching, scattering, or releasing heat, returning the molecule to the ground state.51 
 
 
 
Figure 2.2. Jablonski energy diagram displaying the process of fluorescence 
 
 16
Some of the early work using fluorescence principles for glucose sensing involved 
fluorescence resonance energy transfer (FRET). FRET is the transfer of excited-state 
energy from a donor molecule (D) to an acceptor molecule (A) without the emission of a 
photon. The emission of the donor molecule is at shorter wavelengths and overlaps with 
the acceptor’s absorption spectrum. The energy transfer is a result of dipole-dipole 
interactions between D and A, which lowers the fluorescence of D when both dyes are 
between 20 and 70 Å apart.52 Figure 2.3 demonstrates this principle.  
 
 
Figure 2.3. Relationship between donor-to-acceptor distance and fluorescence spectra intensity 
 
 
When D and A are very close, energy transfer occurs, resulting in a smaller donor 
emission spectra intensity shown in blue. As the distance between D and A increases 
beyond approximately 70 Å, the energy transfer does not tend to occur, and therefore, 
the intensity of the donor emission spectra will increase. 
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The rate of energy transfer depends upon the extent of spectral overlap of the emission 
spectrum of the donor with the absorption spectrum of the acceptor, the quantum yield of 
the donor, the relative orientation of the donor and acceptor transition dipoles, and the 
distance between the donor and acceptor molecules.51 It can be calculated from the 
following: 
6
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where kT is the rate of energy transfer from donor to acceptor, τD is the decay time of the 
donor in the absence of acceptor, R0 is the Förster distance at which energy transfer is 
50% efficient, and r is the donor-to-acceptor distance. The efficiency of energy transfer 
(E) is the fraction of photons absorbed by D that are transferred to A.51 
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This can be seen in figure 2.4. From this diagram, it is evident that for r-values less than 
R0, the energy transfer efficiency rises rapidly towards 100%.  
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Figure 2.4. Dependence of the energy transfer efficiency on the ratio of D-to-A distance to the 
Förster distance 
 
 
The donor-to-acceptor distance is important as the rate of energy transfer is inversely 
proportion to r6. This principle has been studied extensively for glucose sensing. If the 
chemistry can be arranged so that the addition of glucose to the system causes an 
increase in r, then the fluorescence intensity will increase proportionally, as well. 
 
One way to do this is by using a protein called Concanavalin A. Con A is a lectin 
isolated from the jack bean plant, Canavalia ensiformis.53 At physiological pH, it tends 
to exist in tetrahedral form with one saccharide binding site in each subunit, as depicted 
by the red molecules in Figure 2.5.54 If the pH is lowered to less than 5.6 or the 
temperature is less than 4 °C, Con A will take on a dimeric form.55 Con A also contains 
binding sites for specific metals. The first site, S1, can bind a transition metal such as 
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Mn2+, Ni2+, Co2+, Zn2+, or Cd2+. The second site, S2, tends to bind Ca2+ or Cd2+. The 
most typically bound ions are manganese (shown in teal) and calcium (blue).  
 
 
 
Figure 2.5. Concanavalin A tetramer 
 
 
S1 binding must take place before S2 binding can occur and both sites must be occupied 
for the saccharide binding site to be active.55 The sugar binding site is approximately 
350-600 pm wide, 750 pm high, and 1.8 nm deep.55 It has a particular affinity for 
saccharides containing α-D-glucose or α-D-mannose residues.56 Therefore, Con A has 
been a popular topic of research for glucose sensing to treat diabetes. 
 
Some of the earliest work in this area was done by Schultz et al.57 They used 
Concanavalin A as a selective bioreceptor and took advantage of the competitive binding 
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between FITC-labeled dextran and glucose. The Con A was immobilized on the inner 
membrane of a hollow dialysis fiber. The large size of the dextran prevented it from 
leaving the dialysis fiber, while the much smaller glucose molecules were free to diffuse 
in and out, displacing dextran as they became bound to the Con A. Because the dextran 
was labeled with FITC, it fluoresced as the free molecules were excited by an optical 
fiber. The measured fluorescence intensity was proportional to the amount of glucose 
attached to the Con A. The rate of response of this sensor to changes in glucose 
concentration is based on the rate of glucose diffusion through the dialysis fiber wall, the 
competitive displacement of dextran by glucose, and the rate of diffusion of all of the 
components in solution. One major problem with this early sensor is that the Con A had 
to be immobilized to the wall of the hollow fiber, which is not easily reproducible. The 
optical fiber and the dialysis fiber must also be carefully aligned in order to maintain the 
spatial difference in the bound and free dextran and calibration must be performed using 
external standards because of the lack of an internal reference. 
 
One of the first improvements on this sensor was to eliminate the immobilization of Con 
A. Meadows and Schultz used FITC-labeled dextran again and added Rhodamine-
labeled Con A. The labels absorb and fluoresce in the visible region and were useful in 
tracing the following reactions58: 
 
FITC − dextran
(competing analyte)
+  Rh − Con A  
(receptor)
↔ FITC − dextran: Rh − Con A
(competing analyte receptor)
 
Glucose  
(analyte)
+  Rh − Con A  
(receptor)
↔ Glucose: Rh − Con A
(analyte receptor)
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When the dextran is bound to the Con A, the labels are less than 50 Å apart, which is 
close enough to cause significant quenching. As glucose is added, it binds to the Con A, 
freeing dextran. The distance between the FITC and Rh labels is increased, lowering the 
quenching and increasing the signal intensity. This design is a significant improvement 
over the original sensor. The Con A does not need to be immobilized, eliminating the 
lack of immobilization reproducibility and allowing more leeway in the alignment of the 
optical and dialysis fibers. Because all of the reaction components are contained in a 
homogeneous solution, the size of the assay can be reduced from 1-10 mL down to 
around 1 µL. Also, the Rhodamine fluorescence signal tends to be unaffected by the 
energy transfer and is therefore useful as an internal reference for calibration. 
 
The next improvement on this system involved changing the receptor label from 
Rhodamine to tetramethylrhodamine isothiocyanate (TRITC).59 The new label was 
chosen because of the large spectral overlap between the emission spectra of FITC and 
the absorbance spectra of TRITC. The FITC/Rh overlap spans from approximately 515 
to 550 nm while the FITC/TRITC overlap reaches from about 480 to 600 nm, causing 
higher energy transfer efficiency. In addition to the increased energy transfer efficiency, 
the dynamic range of the TRITC-Con A conjugates was improved due to higher dye to 
protein ratios. 
 
These sensors are all based on hollow-fiber systems in which an optical fiber is inserted 
into one end of the membrane. If they were to be used in vivo, there would be an 
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increased risk of infection around the skin that the fiber penetrates. Ballerstadt and 
Schultz designed a sensor that is totally implantable.60 It is comprised of a 
semipermeable membrane containing porous beads with labeled Con A. It is placed 
within 0.5 mm of the skin surface so that light can easily travel to and from the sensor. 
Because some light will be lost due to scattering and absorption of the tissue, the sensor 
must demonstrate a significant fluorescence response to glucose. The sensor uses porous 
Sephadex beads that contain glucose residues. Alexa-488 labeled Con A binds to the 
residues inside the beads and is thereby shielded from light because the absorption 
spectrum of the bead color overlaps with the excitation and emission spectra of the label. 
When glucose is added to the solution, the Con A diffuses out of the beads to bind with 
the glucose. It can then be exposed to light, resulting in an increase in fluorescence 
intensity. This sensor has several advantages. It is small enough to be implantable (0.5 x 
0.2 mm). It also has a response time of only 4 to 5 minutes. Most importantly, though, it 
shows a strong dynamic signal change for glucose concentrations in the range of 0 to 30 
mM. This was achieved because the Sephadex beads provided a large number of glucose 
residues for Con A binding and the dye on the beads prevented excitation light from 
reaching the bound Con A. 
 
Another alternative to the hollow fiber sensor was suggested by Russell and Pishko.61 
They pointed out that the majority of past research was limited to aqueous solutions and 
did not address the issue of assay chemistry encapsulation. They designed a system 
using a PEG hydrogel to incorporate chemically immobilized pendant TRITC-Con A 
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and physically immobilized FITC-dextran. PEG, or poly(ethylene glycol), is 
biocompatible and may improve the stability and solubility of many bound proteins.61 
The sensing was based on FRET in the same manner as the previous aqueous systems. 
The sensors were optimized by adjusting the Con A to dextran ratio to achieve 
maximum glucose sensitivity and the response was found to be linear up to 600 mg/dL, 
which is reasonable for physiological use. The measured response time was between 10 
and 12 minutes, but the limiting factor was diffusion time. This time could potentially be 
lowered by creating smaller spheres, thereby reducing the diffusion distance. If 
contained in a capsule such as a diffusion membrane, the tiny hydrogel spheres have the 
potential for transdermal injection, creating a minimally-invasive “smart tattoo” for 
glucose sensing. 
 
In order to increase the dynamic response of the competitive binding assay, the dextran 
molecule was replaced with a spherical dendrimer molecule.62,63 Dendrimers are 
repeatedly branched structures consisting of a core molecule surrounded by consecutive 
branching layers. In this embodiment, a fourth-generation polyamidoamine (PAMAM) 
glycodendrimer was used as the competing ligand, as shown in Figure 2.6. In the 
absence of glucose, the Con A tetramers are bound to the glycodendrimer molecules. As 
glucose is added to the system, it binds to the receptors on the Con A, competitively 
displacing the dendrimers, resulting in an increase in the intensity of the dye label 
affixed to the Con A as the dye is no longer quenched. The spherical shape of the 
dendrimer only allows a single bond to be formed with each Con A tetramer, eliminating 
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the potential for incomplete dissociation. This assay is fully reversible and has a larger 
dynamic response to physiological concentrations than the previous dextran-based assay. 
This assay could also be encapsulated in order to introduce it as a semi-invasive sensing 
modality in the body. 
 
 
 
Figure 2.6. Schematic showing the Con A-glycodendrimer assay system 
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The fluorescence-based affinity sensor approach has several advantages. First of all, it is 
minimally-invasive and does not require a blood sample for measurement. The 
fluorescence response is determined by the competitive equilibrium between glucose and 
a ligand and not the rate of consumption as in enzyme-based sensors. Therefore, kinetic 
factors such as membrane permeability and fouling have less impact. High selectivity 
and sensitivity can be obtained by choosing the optimal binding protein and competitive 
ligand. The potential system is very small, allowing the response time to be on the order 
of minutes.57 Con A also has several advantages for glucose sensing. It has a reversible 
binding mechanism, so it does not use up glucose or other reagents. It is independent of 
oxygen concentrations and there are not many competing glucose-like molecules in 
interstitial fluid, so the sensing will not be inadvertently hindered. Con A is also 
inherently stable.64 Fluorescence-based sensing is fast, reagentless, minimally-invasive, 
and tends to be highly specific.65 Though there are not currently any optically-based 
sensors on the market for glucose, the advantages make it a likely possibility for the 
future. 
 
Summary 
Continuous glucose monitoring has been shown to have many benefits, including tighter 
glycemic control and a reduction in the incidence of hypoglycemic events. Long-term 
tracking can be used by physicians to advise patients on dietary and treatment 
recommendations, as well. Transdermal meters, such as the GlucoWatch, draw glucose 
through the skin to measure concentration. While this system is advantageous because it 
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avoids puncturing the skin, the GlucoWatch suffered from several technological issues 
and was withdrawn from the market in 2007. Another noninvasive device, the Pendra, 
uses impedance to determine glucose levels. Though it received its CE mark and was 
being distributed in Europe, the Pendra had a number of drawbacks including the 
incompatibility of the system with the skin of about 30% of potential users. Additionally, 
the device experienced significant error issues, leading Pendragon to cease sales in 2004. 
GlucoDay is a microdialysis device that samples interstitial fluid through a subcutaneous 
catheter and detects glucose concentration using a glucose oxidase reaction. The linear 
range is excellent, but the device experiences an extensive lag time and patients 
experienced high levels of discomfort during use. Furthermore, the device is only 
approved for 48 hour clinical use in Europe. In the US, there are currently four CGM 
systems that continuously measure glucose using a transcutaneous glucose oxidase 
sensor including the DexCom Seven, the FreeStyle Navigator, the Medtronic MiniMed 
Guardian, and the Medtronic MiniMed Paradigm. These systems have shown a lot of 
promise in terms of helping patients achieve better glycemic control, but the sensor 
lifetime is relatively short and transcutaneous devices introduce the possibility of 
infection. Optical methods are advantageous because they allow for the opportunity of 
noninvasive or minimally invasive sensing. Fluorescence-based sensing, in particular, is 
fast, reagentless, and tends to be highly specific. Though there are not currently any 
optically-based glucose sensing devices on the market, they have the potential to 
improve continuous glucose monitoring by offering a sensitive, stable response for long-
term glucose detection. 
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CHAPTER III 
MICROPORATION FOR ANALYTE DETECTION* 
 
Introduction 
Polymer hydrogels have been used to encapsulate fluorescently labeled molecules in 
order to sense a variety of analytes.61,66-71 Poly(ethylene glycol) (PEG) is one such 
polymer that is widely used for biosensing because of its inherent biocompatibility.72-75 
PEG hydrogels are created via cross-linking of the polymer chains, creating a mesh that 
retains the larger sensing molecules, while allowing for efficient diffusion of small 
analytes. The mesh size of pure poly(ethylene glycol) diacrylate (PEG-DA) has been 
reported to be between 8.6 and 10.8 Å.76-78 The mesh size of the hydrogels can be 
increased by introducing aqueous solution to the precursor solution, reducing the 
potential for cross-linking. The ratio of aqueous solution to PEG-DA has been shown to 
alter the mesh size considerably.77 Furthermore, the addition of aqueous solution alters 
the mechanical properties of the polymer as increased hydration leads to decreased 
strength. The aqueous gels also require continuous hydration after formation of the 
hydrogel to prevent drying. This increase in mesh size does allow for increased diffusion 
of small analytes through the hydrogel which could speed up sensor response time.  
 
 
____________ 
* Part of the data reported in this chapter is reprinted with kind permission from Spring Science + 
Business Media: Journal of Fluorescence, Microporated PEG Spheres for Fluorescent Analyte Detection, 
17, 2007, 57-63, Rounds RM, Ibey BL, Beier HT, Pishko MV, Coté GL. 
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However, in applications focusing on entrapping larger assay molecules within the 
hydrogel matrix, increased leaching typically results, thus limiting the functional life 
span of the sensor. 
 
For assays that detect a spatial displacement of molecules that bind to the sensing 
element inducing a change in fluorescence through a fluorescence resonance energy 
transfer (FRET) reaction or steric quenching, the current hydrogels do not allow for 
sufficient mobility of the components without increasing the hydrogel mesh size, which 
can lead to increased leaching. For example, several approaches for fluorescent glucose 
sensing function successfully in solution, but lose activity upon hydrogel encapsulation 
because of the physical inability of the assay chemistry to completely dissociate and re-
associate within the confines of the hydrogel network.61,62 One such sensor is based on a 
FRET reaction that occurs between fluorescein isothiocyanate (FITC)-labeled dextran 
and tetramethylrhodamine isothiocyanate (TRITC)-labeled concanavalin A (Con A) that 
are within close proximity, as the absorption spectra of TRITC heavily overlaps the 
emission spectrum of FITC.57-59 Con A, a lectin, or highly specific sugar-binding 
protein, derived from the Jack bean plant, has an inherent affinity for saccharides such as 
dextran and glucose.53,56 The sensor is created by allowing labeled dextran to bind with 
the labeled Con A, bringing the independent fluorophores within 50 Å, close enough to 
cause significant quenching of the FITC signal.59 As glucose is added to the solution, 
some of the dextran molecules are displaced, increasing the distance between the 
fluorophores, thereby lowering the quenching and increasing the signal intensity. This 
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process has been shown to be reversible, meaning that as less glucose becomes present 
in the system, the dextran molecule will resume conjugation with the Con A protein and 
the FITC fluorescence will again be quenched. In order to contain this chemical assay in 
a protected environment in which it could eventually be implanted into the human body, 
PEG encapsulation has been investigated.61,79 Pure 100% PEG was disregarded because 
of the limited motility it offered to the entrapped molecules. Higher hydration ratios 
have been explored, but they resulted in leaching of the sensor chemistry as the 
increased mesh size could not contain the assay for long periods of time. In order to 
overcome this, a polymer ester complex (poly(ethylene glycol)-NHS) was used to cross-
link the sensing elements to the backbone of the polymer matrix while still allowing 
freedom to bind and unbind. This procedure showed potential, but resulted in a large 
reduction in the response of the sensor due to the decreased motility offered by the 
tethering ester complex.61 
 
Previous Methods 
Several previous attempts to improve sensor response have been made using various 
hollow embodiments. Ballerstadt and Schultz created a fluorescence affinity hollow fiber 
sensor based on the competitive binding of fluorophore-labeled Con A to glucose 
residues inside Sephadex beads.60,64 As glucose diffuses into the sensor, the Con A 
molecules are displaced from the beads, and being no longer shielded from the excitation 
light, display an increase in fluorescence intensity. The main problem with this sensor 
was leakage of the Con A through the sealant/membrane interface, reducing sensor 
 30
lifetime and exposing the surrounding tissues to the assay components. Barone, Parker, 
and Strano proposed a single-walled carbon nanotube-based (SWNT) optical sensor that 
is coated in a hydrogel matrix to improve biocompatibility and prevent leakage.80 The 
SWNTs fluoresce from 900 to 1600 nm and are coated with a glucose analogue such as 
dextran. A glucose-specific protein like Con A binds to the dextran coated walls, 
attenuating the fluorescence signal, until glucose is introduced, competitively binding 
and freeing the Con A. This is potentially advantageous because SWNTs are 
photobleaching-resistant, but results so far have been limited to theoretical modeling. 
Chinnayelka and McShane have created microcapsules containing a competitive binding 
assay by using a layer-by-layer fabrication technique.81,82 Initially, dissolvable resin 
microparticles were coated with FITC-dextran and TRITC-Con A layers and an outer 
polymer layer.81 Then the core was dissolved to produce a hollow microcapsule lined 
with immobilized Con A and dextran. This approach had a limited response due to the 
low assay concentration within the walls and a significant drop in pH was used to 
dissolve the inner core that could be harmful to many sensing assays. This system was 
improved upon by first creating hollow spheres and then filling them with a competitive 
binding assay that was free to move within the microcapsules.82 This method is 
promising, but the loading of the microcapsules is diffusion-limited and requires 
excessive amounts of expensive assay components to drive the particles into the 
capsules. 
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Methods of Poration 
Our group has devised a simple approach of porating PEG microspheres in order to 
increase assay motility while simultaneously preventing assay leaching. A variety of 
methods exist for creating porous hydrogels, including the porosigen technique, phase 
separation technique, foaming technique, and cross-linking of individual hydrogel 
particles. 83 The porosigen or porogen technique is particularly useful for our 
applications as it can be used in many different polymers, is capable of creating a variety 
of pore sizes, and can create individual cavities as opposed to channels that open to the 
surface, which would allow the assay the potential for escape. In order to create these 
cavities, a water-soluble porogen material, such as sucrose, is dispersed throughout the 
hydrogel precursor solution. After polymerization, the porogen is dissolved and 
dispersed, leaving cavities in the hydrogel matrix that are dependent on the size of the 
initial sucrose crystals.84 Similar processes have been used previously for drug delivery 
and tissue engineering, but have been focused primarily on increasing transport rates 
rather than retaining molecules.85,86 Applied to sensing, this process of poration creates 
small cavities within the hydrogel that contain the assay component in aqueous solution. 
The cavities allow for a response similar to that in pure aqueous solution by providing 
more room for increased assay component motility, while simultaneously reducing 
leaching through the fine mesh of the 100% PEG hydrogel. 
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Microsphere Fabrication 
Three hydrogel compositions were created for comparison: 100% PEG, 50% aqueous 
PEG, and microporated 100% PEG. The 100% pure PEG hydrogel solutions were 
composed of liquid PEG-DA, while the 50% aqueous hydrogels were made with 50% 
PEG-DA and 50% water. A pH-sensitive assay of 10 mg/mL FITC-dextran (MW 
10,000, 1% v/v) was added to test the sensing capabilities of each composition. A 
photoinitiator, Darocur, was added to promote cross-linking during polymerization (1% 
v/v). Spherical particles were created using an emulsion technique and cured via a 2.0 
second UV exposure, as shown in Figure 3.1 (300 mW/cm2, λpeak = 365 nm, EFOS 
Ultracure 100SS Plus).  
 
 
 
Figure 3.1. Sphere manufacture setup 
 
 
In order to test the glucose sensing capabilities of the hydrogel compositions, a 
previously devised FITC-dextran/TRITC-Con A assay was incorporated.58,59 An 
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additional composition was also created with the TRITC-Con A chemically immobilized 
through linkage to PEG-NHS, as done in previous work.61 
 
To induce microporation within the hydrogels, a powdered combination of mannitol and 
fluorophore was added to the pure PEG precursor solution. The powders were formed 
through lyophilization of 100 mg of mannitol, 100 µL of fluorophore assay solution and 
900 µL of 0.1 M PBS. Large aggregations of the powder were separated by sonicating 
the PEG solution for 15 minutes prior to use. After polymerization, the spheres were 
soaked in PBS to dissolve the mannitol porogen. The porogen was then removed by 
washing, leaving pockets in the hydrogel containing the sensing elements in aqueous 
solution, as shown in Figure 3.2. 
 
 
 
Figure 3.2. Mannitol dissolving from a sphere over time, leaving cavities filled with a glucose 
sensitive assay in solution 
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Detection and Imaging 
A fluorescence detection system from Photon Technologies Inc. consisting of a mercury 
arc lamp, an excitation monochrometer, a sample chamber, an emission monochrometer, 
and a PMT was used to collect fluorescence at 90° (PTI, Lawrenceville, NJ). The spheres 
were placed in a microcuvette (Ocean Optics, Dunedin, FL) with 0.1 M PBS and excited 
with 480 nm light. For pH sensing, spectra were acquired from 500 to 550 nm and for 
glucose sensing, spectra were taken from 500 to 600 nm to include the FITC peak 
around 520 nm and the TRITC peak at approximately 580 nm. Changes in pH were 
induced using 1 M HCl and verified using a pH meter (420 A+, Orion; electrode 5990-
30, Cole-Parmer, Vernon Hills, IL). 
 
For sphere characterization, fluorescent images were acquired using an inverted 
microscope (Nikon CFI60, East Rutherford, NJ) containing two emission filters and 
differential interface contrast (DIC) optics (Chroma DIC, FITC, Filter Sets, 
Rockingham, VT). Fluorescent and DIC images were obtained using standard light 
microscopy (MetaVue Software, Sunnyvale, CA) and a CCD camera (Roper Scientific 
Photometrics Coolsnap HQ, Duluth, GA) with a 100 ms integration time. Confocal 
microscopy was used to determine the degree of poration using 2D fluorescent images at 
the point of maximum diameter of the sphere. A program was generated using the image 
processing toolbox with Matlab to calculate the fraction of fluorescent pixels to 
background pixels in order to estimate the total percent poration. 
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Sphere Characterization 
In order to determine the feasibility of our new microporated sphere moiety, FITC 
fluorophores were encapsulated in a PEG-DA hydrogel. FITC undergoes a change in 
fluorescence intensity in the presence of H+ ions and was therefore used to detect 
changes in pH. The distribution of sphere diameter for a set of 60 spheres made in 3 
separate batches can be seen in Figure 3.3. The average sphere diameter was found to be 
about 370 µm, but the distribution is positively skewed due to the presence of a few 
larger spheres. It is possible that there could have been a few corresponding smaller 
spheres, but at sizes under 100 µm, the spheres tend to float and could be lost during the 
washing process. The optimal sphere size has been previously determined to be 100 µm 
based on photon flux and fluorescence intensity, but may be larger due to the additional 
light scattering caused by the cavities.87 
 
 
Figure 3.3. Sphere diameter distribution of 60 spheres sampled from 3 batches 
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Fluorescent images, generated using confocal microscopy, were taken of 52 individual 
microspheres to determine the extent of poration. The number of fluorescent pixels, 
given a threshold, was counted and divided by the total sphere pixel area to yield a 
percent poration for each sphere that is shown in Figure 3.4. 
 
 
 
Figure 3.4. The distribution of sphere poration 
 
 
The percent pore volume was estimated using image analysis and found to be about 
15.12% with a standard deviation of 2.24%. Figure 3.5 shows the location of the 
micropores within the sphere in A and the corresponding entrapped fluorophore in B. 
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The fluorophore is primarily contained within the cavities of the microporated spheres, 
which allows for easy detection, but makes the sensors less prone to surface leaching. 
 
 
 
Figure 3.5. A sphere of approximately 400 µm diameter with micropores (A) and fluorophore 
contained within the cavities distributed throughout the sphere (B)  
 
 
Sensor Response Time 
As the cross-linking density increases, the diffusion coefficient through a hydrogel 
decreases.88 Therefore, analytes should diffuse more quickly through the 50% PEG than 
through the 100% PEG, and much faster in free solution where there are few barriers. 
The microporated spheres were designed to decrease the time response by alternating 
areas of dense polymer and pockets of solution. Combining the two environments to 
create a pure PEG sphere with 15% poration, should result in a noticeable decrease in 
the transport time of small analytes. 
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Analyte diffusion through the polymer can be described by Fick’s law of diffusion: 
 
,
A
A x AB
dcj D
dx
= −  
where 
,A xj is the diffusive flux in kg/m2s of analyte A at point x, cA is the concentration 
of A in kg/m3, x is the distance in m, and DAB is the diffusivity of A in the polymer matrix 
B in m2/s.89,90 Theoretically, the sensor should respond as soon as the analyte has 
reached the first fluorophore-filled cavity and continue to increase in intensity as the 
analyte travels towards the center of the sphere, as shown in Figure 3.6. 
 
 
 
Figure 3.6. Diagram of a sphere showing a potential 1D path of analyte transport and the 
corresponding signal intensity 
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Glucose, for example has a diffusivity of approximately 6.8 x 10-6 cm2/s in aqueous 
solution, while tetramethylrhodamine, a fluorescent tracer on the same order of 
molecular weight as glucose has a diffusivity of about 2.99 x 10-9 cm2/s in PEG-DA.76 
For 1-D diffusion, the total time can be found with respect to the mean-square 
displacement <x2> and diffusivity, D.89 
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As shown in Figure 3.7, for a sphere of diameter 370 µm, it should take about 25 
seconds to reach the center of the sensor in solution, while travelling through pure PEG 
would take significantly longer. 
 
 
 
Figure 3.7. Approximate distance traveled by glucose over time in solution and through pure PEG 
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The time response of the sensors was measured by inducing a change in pH and 
measuring the resulting signal over time. A steady baseline intensity was established and 
then 5 µl of HCl was added. As shown in Figure 3.8, the assay responded immediately in 
free solution and was quick enough to capture the initial buffering activity. The time 
response of the solid PEG spheres is much slower, but microporation improves the 
reaction time, nearly matching that of the 50% PEG hydrogel. This could be further 
improved by reducing the sphere size so there is less distance for the analyte to travel 
and increasing the percentage of pore volume within the microporated spheres. 
 
 
 
Figure 3.8. Sensor time response to a pH change induced by 5 µL of HCl in the three sphere sets 
versus free FITC-dextran in solution 
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Sensor Stability 
Sensor stability was monitored using spectra taken daily for a period of one month. Prior 
to measurement, the buffer solution surrounding the spheres was removed and fresh PBS 
was added so that any fluorophore that was initially on the sphere surface, but then fell 
into solution would be excluded from the intensity readings. Intensities for each sphere 
composition were normalized for comparison and Shewhart control charts were created 
using JMP, a statistical software package, as shown in Figure 3.9 (Individual 
Measurement Chart, JMP 6, SAS Institute, Cary, NC).91,92 
 
 
 
Figure 3.9. Control charts for sensor stability over one month showing the upper (UCL) and lower 
control limits (LCL) for (a) 100% PEG, (b) 50% PEG, (c) porated 100% PEG, and (d) free solution. 
Only the 50% PEG experienced a statistically significant decrease in intensity due to fluorophore 
leaching 
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The upper (UCL) and lower control limits (LCL) are defined as: 
 
UCL X k
LCL X k
σ
σ
= +
= −
 
where X is the mean of the individual measurements, k is a multiple of the standard 
error set at 3, and σ  is the standard deviation.91 The 100% PEG spheres, shown in part 
a, remained relatively stable as the fine mesh size limits fluorophore leaching and 
promotes sensor stability over time. The 50% PEG spheres, on the other hand, showed a 
large decrease in intensity in part b, which is attributed to significant fluorophore 
leaching. The porated PEG spheres, shown in part c, performed well, remaining 
relatively steady throughout the month as the dense polymer matrix retained the majority 
of the sensing molecules. The free FITC in solution, though stable, shows slight day to 
day variability in part d, potentially due to a combination of source variability, 
temperature fluctuation, photobleaching, and changes in sphere packing.  System noise 
is similarly evident in each of the sphere sets, but the overall statistical trends are 
notable. 
 
Assay Motility 
Sensor motility was assessed using a glucose sensitive assay that is based on a binding 
reaction with FITC-dextran and TRITC-Con A. A 1000 mg/dL glucose change was 
induced and the resulting change in fluorescence intensity was measured, as shown in 
Figure 3.10. The response was minimal in the 100% PEG spheres and the 50% PEG 
spheres, most likely because of the immobilization of the assay components within the 
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PEG mesh, allowing little room for unbinding to occur. The PEG-NHS spheres used in 
previous research have a portion of the sensor chemistry bound directly to the polymer 
backbone in attempt to minimize leaching, which also appeared to reduce the sensor 
activity in combination with the limiting mesh size.61 The response in the microporated 
spheres was, however, much faster than that of the other sphere sets. It was also only 
slightly slower than the response in solution and comparable in relative intensity. 
 
 
 
 
Figure 3.10. Sensor response to 1000 mg/dL glucose change 
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Conclusions 
An ideal hydrogel encapsulation would retain sensing elements while allowing for 
efficient diffusion of the analyte of interest. Microporation of poly(ethylene glycol) 
spheres creates cavities where analytes may quickly diffuse and interact with the sensing 
elements. Pure 100% PEG spheres have a very slow response time, which is 
significantly improved by microporation, nearly matching the response rate of 50% PEG 
hydrogels. Loose mesh sizes promote fast analyte transfer, but also tend to allow the 
assay chemistry to leach out into solution, reducing the functional sensor lifetime. 
Microporation allows for the use of a fine mesh size to minimize leaching without 
limiting molecule mobility. Over a one month period, the microporated spheres 
maintained relatively consistent intensity levels, while the 50% PEG spheres 
experienced a significant decrease in fluorescence over time. Additionally, the 
microporated PEG provided adequate space for increased assay motility, allowing a 
binding reaction with FITC-dextran and TRITC-Con A to occur nearly unhindered while 
the other sphere compositions displayed minimal responses due to their restrictive mesh 
sizes. Microporation of PEG hydrogel spheres creates cavities of aqueous solution in 
which the assay chemistry is free to react with small analytes, while limiting leaching, 
promoting both functionality and stability of the encapsulated sensors.  
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CHAPTER IV 
MINIMIZING THE HOST RESPONSE* 
 
Host Response to Implant 
The host response to the injury incurred upon device implantation depends on many 
factors including the extent of injury, the loss of basement membrane structures, blood-
material interactions, provisional matrix formation, the extent of cellular necrosis, and 
the degree of the inflammatory response, as well as the size, shape, and chemical and 
physical properties of the implant material. The general sequence of events following the 
implantation is shown in Figure 4.1. The initial inflammatory response is triggered by 
injury to vascularized connective tissue which leads to immediate development of the 
provisional matrix consisting of fibrin, activated platelets, inflammatory cells, and 
endothelial cells. This serves to seal the wound and initiate further repair. Acute 
inflammation involves the exudation of fluid and plasma proteins and the emigration of 
leukocytes, and can last for minutes to hours to days, depending on the extent of the 
injury. Polymorphonuclear leukocytes, or neutrophils, are the first cells to appear, 
attempting phagocytosis, the engulfing and degradation of solid particles. Monocytes 
migrate to the wound where they differentiate into macrophages. The macrophages clean 
up the wound site, removing foreign material, bacteria, and dead cells, and recruit cells  
 
____________ 
* Part of the data reported in this chapter is reprinted with permission from Gant RM, Hou Y, Grunlan M, 
Coté GL. Development of a self-cleaning sensor membrane for implantable biosensors. Journal of 
Biomedical Materials Research Part A 2009; 90A(3): 695-701, by Wiley. 
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such as fibroblasts and endothelial cells. Due to the relative size disparity between the 
cells and the implant, phagocytosis is usually unsuccessful, resulting in frustrated 
phagocytosis and the release of lysozymes and oxidative products. The following 
chronic inflammation is typically short, lasting hours to days, and is confined to the 
implant site. This stage is less histologically uniform than acute inflammation and is 
generally characterized by the proliferation of blood vessels and connective tissue along 
with the presence of macrophages, monocytes, and lymphocytes, which release 
substances that cause the migration and proliferation of the fibroblasts.  
 
 
 
Figure 4.1. Physiological responses to an implanted biosensor leading to the formation of a fibrous 
capsule 
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Within a day of implantation, healing is activated by the products secreted by 
macrophages, including neutral proteases, chemotactic factors, arachidonic acid 
metabolites, reactive oxygen metabolites, complement components, coagulation factors, 
growth-promoting factors, and cytokines. Fibroblasts and vascular endothelial cells 
proliferate and begin to form granulation tissue several days after implantation at the 
start of the repair phase. New blood vessels are formed and fibroblasts synthesize 
collagen and proteoglycans. Macrophages fuse to form foreign-body giant cells in an 
attempt to phagocytose the implant while myofibroblasts begin the process of 
contraction, drawing the edges of the wound together. During the foreign body reaction, 
relatively smooth surfaces elicit a layer one to two cells in thickness, while rougher 
surfaces have more complex responses. Though the cells may remain on the surface of 
the implant indefinitely, it is not known if they remain activated or become quiescent. 
The final stage of the wound healing response after implantation of a biomaterial is 
typically fibrosis or fibrous encapsulation. As the surrounding tissue heals, regenerating, 
remodeling and replacing the injured tissue, connective tissue continues to proliferate, 
forming an avascular fibrous capsule. Spindle-shaped fibroblasts and a small number of 
macrophages are usually associated with the capsule, which is formed primarily of 
collagen and can range in size from about 0.05 to 1.5 mm. The fibrous encapsulation is 
influenced by many factors, including structure and morphology of the material, size of 
the implant, implantation site, and material biodegradability.93-102  
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Biocompatibility 
The widely accepted definition of biocompatibility is “the ability of a material to 
perform with an appropriate host response in a specific application”, which was decided 
upon at a consensus conference of the European Society for Biomaterials.103 It has been 
suggested that though this definition is functional, it offers no insight as to extent of 
biocompatibility or a basis on which to improve the biocompatibility of a material.94,104  
Currently, there is no list of materials considered safe or unsafe. Instead, each potential 
material must be evaluated for its specific purpose in a specific location. In addition to 
the effects from the implant on the host tissues, the effects of the host on the implanted 
device, or sensocompatibility, must also be considered to minimize medical 
complications and device failure.105 
 
Biofouling and the scar-like, avascular fibrous encapsulation that eventually surrounds 
implanted sensors can reduce analyte diffusion and perfusion, causing a decrease in 
sensor response. Rebrin et al. show the decay of glucose sensor response as a function of 
implantation time in subcutaneous tissue.106 The signal loss is extensive, in some cases 
dropping to nearly 20% of the original intensity over a period of several hours. 
Sharkawy et al. show that the fibrous capsule surrounding a subcutaneously implanted 
sensor imposes a significant diffusion barrier to glucose, halving the diffusion rate and 
increasing the lag time of the sensor by as much as threefold.107 A diffusion barrier is 
imposed by the dense fibrous tissue while a perfusion barrier exists due to the capsule 
avascularity. Dungel et al. demonstrate the loss of sensor function without functional 
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blood vessel access.108 In addition, local analyte levels could be altered by the metabolic 
changes in the surrounding cells as wounded tissue causes cells to function in a 
hypermetabolic state.109 Biofouling and fibrous encapsulation can also cause problems in 
optical biosensors by reducing the signal via additional light scatter and absorption. 
 
Many methods have been suggested to combat biofouling, including hydrogel overlays, 
phospholipid-based mimicry, flow-based systems, Nafion membranes, surfactant 
modification, naturally derived membrane materials, covalently modified membranes, 
diamond-like carbon coatings, and topology treatments.110 None of these strategies can 
completely eliminate biofouling, nor do any of these approaches appear to stand out as 
most effective. 
 
Smart Materials 
Smart materials undergo rapid, reversible conformational or phase transitions triggered 
by small changes in the local environment. Stimuli include temperature, pH, light, 
electric field, stress, pressure, metal ions, glucose or other biochemical stimuli.111-113 
Hydrogels are three-dimensional networks of hydrophilic polymers that do not dissolve, 
but swell in water and were the first biomaterials designed for use in the human body.112 
The amount of water uptake depends on the polymer structure and type and degree of 
cross-linking. 
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Thermosensitive hydrogels exhibit a phase transition, existing in a swollen hydrophilic 
state at temperatures below the volume phase transition temperature (VPTT) due to 
hydrogen bonding with water molecules, and contracting into a collapsed hydrophobic 
state as the temperature is raised above the VPTT, as shown in Figure 4.2. Above the 
VPTT, the efficiency of the hydrogen bonding becomes insufficient to maintain the 
structure in solution, as the hydrophobic interactions between the polymer molecules 
become more favorable than the interactions between the polymer and water.114 
 
 
 
Figure 4.2. Schematic of thermosensitive hydrogel response: At temperatures below the VPTT, the 
gel exists in a swollen, hydrated state, while increasing the temperature above the VPTT causes the 
gel to expel water, resulting in structural collapse 
 
 
The study of thermoresponsive gels was first reported in 1978 when Tanaka examined 
the dynamics underlying the collapse of the polymer network in polyacrylamide gels.115 
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Since then, the dramatic phase transition has been used in a variety of ways including as 
motors/actuators116,117, in drug delivery118-121, gene delivery122, and for cell release in 
tissue engineering and artificial organ development123-125. For example, Shimizu et al. 
cultured cells on a thermoresponsive surface and were able to release the confluent cells 
as an entire sheet of cardiac tissue.126 Stimuli-responsive polymers have also been used 
for culturing cells that are too sensitive to be enzymatically detached from the culture 
dish.123  
 
The most extensively studied synthetic responsive polymer is poly(N-
isopropylacrylamide) (PNIPAAm) because of the relatively sharp transition near body 
temperature.127-129 In 1968, Heskins and Guillet first reported that PNIPAAm 
precipitates from aqueous solution at about 31 °C, depending on polymer 
concentration.130 The enthalpy of phase transition for PNIPAAm is about 6.3 kJ/mol.128 
This is similar to H-bond energy, but hydrogen bonding is unlikely to be the only factor. 
In addition to polymer-water hydrogen bonding, polymer-polymer hydrophobic 
reactions are also likely to be involved.  
 
Self-cleaning Sensor Membrane 
A “self-cleaning” hydrogel has been developed with temperature-dependent 
hydrophobicity that could limit protein and cellular adhesion. Thermoresponsive 
hydrogels are advantageous for in vivo use as they undergo a sharp volume change over 
a short range of temperature. Furthermore, the high water content of the hydrogels 
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makes them relatively flexible, minimizing the local tissue irritation that could occur 
with a stiffer material. However, the highly swollen nature of the polymers also 
contributes to poor mechanical integrity.119,131,132 The mechanical properties may be 
improved by copolymerization with another monomer, but this can alter the transition 
temperature, which would not be ideal for in vivo use.133 Nanocomposite hydrogels have 
been prepared by introducing polysiloxane colloidal nanoparticles into PNIPAAm 
hydrogel matrices. This addition does not significantly alter the phase transition 
temperature, but does increase the mechanical strength of the hydrogels, increasing the 
potential for in vivo success.134 This nanocomposite PNIPAAm material is described for 
the ultimate application as a “self-cleaning” sensor membrane for an implantable optical 
sensor targeting glucose as the analyte of interest. Figure 4.3 demonstrates the anti-
fouling properties of the material as it is activated by thermal fluctuations. At room 
temperature, the hydrogels are hydrophilic and swollen with water. As the temperature is 
increased above the VPTT, the gels become more hydrophobic and expel water, 
resulting in a collapsed structure. Theoretically, the combination of the mechanical 
stretching forces from the swelling and deswelling behavior along with the change in 
hydrophobicity may prevent proteins and cells from adhering to the surface of the 
material. 
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Figure 4.3. Swelling and deswelling behavior of the self-cleaning membrane on a sensor surface 
 
 
Three PNIPAAm-based hydrogels, A, B, and C, were prepared along with a PEG 
hydrogel control, D, to assess the potential of the materials for use as a self-cleaning 
membrane for implantable biosensors. The composition of each precursor solution is 
shown in Table 4.1. The solutions were purged with nitrogen for 10 minutes and injected 
into a glass mold, which was then sealed and submerged into an ice water bath (~7 °C). 
The solutions were photopolymerized via 10 minute exposure to UV light (9 mW/cm2, 
λpeak = 365 nm, UVP UV-Transilluminator). The hydrogels were thoroughly rinsed with 
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DI water and soaked for at least 24 hours to remove impurities and allow time for 
adequate hydration. A pure PNIPAAm hydrogel, A, was used as a comparison for the 
properties of the nanocomposite hydrogel, B. The pure PNIPAAm hydrogels are limited 
by diminished strength when they are in a highly hydrated state.119,132 In order to 
overcome this, nanocomposite hydrogels were prepared with polysiloxane colloidal 
nanoparticles. Higher mechanical strength is achieved with increasing nanoparticle 
concentrations, but there is a tradeoff with optical transparency.134 The concentration of 
1 wt% was chosen to incorporate into the PNIPAAm hydrogels as this allows sufficient 
light propagation for biosensing purposes while improving strength. In addition, the 
PNIPAAm-based hydrogels were photopolymerized at ~7 °C as polymerization at 
temperatures below the lower critical solution temperature (LCST) has been shown to 
produce gels with homogeneous morphology, resulting in optically clear hydrogels with 
improved mechanical integrity.135 Poration was achieved in composition C by adding 
20% PEG (MW 1000) to the precursor solution. After photopolymerization, the porogen 
was removed by extended soaking for at least 72 hours in DI water. A poly(ethylene 
glycol) diacrylate solution was prepared in composition D as a non-thermoresponsive 
control.61,136 Aqueous PEG hydrogels were made with 60% v/v poly(ethylene glycol) 
diacrylate (MW 575) and 1% v/v Darocur 1173 photoinitiator and photopolymerized at 
room temperature for 3 seconds. 
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Table 4.1. Composition of the hydrogel materials 
Hydrogel Aqueous Precursor Solution 
(A) PNIPAAm NIPAAm monomer (12.5 wt%) 
BIS cross-linker (2 wt%) 
Irgacure photoinitiator (1 wt%) 
(B) Nanocomposite PNIPAAm NIPAAm monomer (12.5 wt%) 
BIS cross-linker (2 wt%) 
Irgacure photoinitiator (1 wt%) 
Polysiloxane colloidal nanoparticles (1 wt%) 
(C) Porated nanocomposite 
PNIPAAm 
NIPAAm monomer (12.5 wt%) 
BIS cross-linker (2 wt%) 
Irgacure photoinitiator (1 wt%) 
Polysiloxane colloidal nanoparticles (1 wt%) 
Leachable PEG, MW 1000 (20 wt%) 
(D) PEG PEG-DA, MW 575 (60% v/v) 
Darocur photoinitiator (1% v/v) 
 
 
Temperature-dependent Equilibrium Swelling 
The temperature-dependent equilibrium swelling behavior of each of the materials was 
measured from 10 to 50°C. Polymer slabs (1 cm x 1 cm x 500 µm) were submerged in 
DI water of a specific temperature for 24 hours and then the wet weight (wwet) was 
measured. The dry weight (wdry) was determined by drying the polymer slabs in an oven 
at 40°C for 24 hours before measurement. The swelling ratio is defined as: 
 
dry
drywet
w
ww
SR
−
=  
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Figure 4.4 shows that the PNIPAAm materials, A, B, and C, are significantly more 
hydrated at lower temperatures and contain much less water at temperatures above the 
VPTT. In contrast, the PEG hydrogel, D, served as a control, remaining at a constant 
level of hydration over the entire range of temperatures studied. As previously shown, 
the addition of the polysiloxane nanoparticles does not alter the VPTT as it would if 
NIPAAm was copolymerized with a second monomer.133,134,137 
 
 
 
Figure 4.4. Volume equilibrium swelling ratios as a function of temperature for (A) pure PNIPAAm, 
(B) PNIPAAm with nanoparticles, (C) porated PNIPAAm with nanoparticles, and (D) 60% PEG 
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Swelling and Deswelling Kinetics 
The swelling and deswelling kinetics were studied by measuring the amount of time it 
took for materials to transition when the temperature was varied between 25 and 37 °C. 
The hydrogels were maintained at 37 °C for 24 hours and introduced to 25 °C solution. 
The wet weight of each material was then measured every 5 minutes for 1 hour. The 
solution was maintained at 25 °C for the following 24 hours to allow time for the 
material to fully equilibrate before it was measured again. The temperature was raised to 
37 °C again and measurements were made for 1 hour, followed by the measurement of 
the fully transitioned hydrogel after an additional 24 hours. 
 
The polymers reach 90% hydration in ~25 to 30 minutes, as shown in Figure 4.5. After 
the temperature is increased, the hydrogels exhibit an initial rapid shrinking, followed by 
slower deswelling. This slower deswelling rate may be due to the restriction of water 
expulsion from the center of the hydrogels caused by the immediate surface shrinking.119 
The swelling and deswelling processes are diffusion-dependent. Hence, the swelling 
time is proportional to the square of the size of the material and the diffusion 
coefficient.138 In order to minimize the time of swelling, the smallest dimension, or 
thickness, could be minimized. 
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Figure 4.5. Phase transition time plot showing material swelling upon cooling to 25 °C, followed by 
deswelling when the temperature was raised to 37 °C for (A) pure PNIPAAm, (B) PNIPAAm with 
nanoparticles, and (C) porated PNIPAAm with nanoparticles 
 
 
Glucose Diffusion 
A diffusion study was performed to analyze the transport of small analytes through each 
material using glucose as an example analyte as it is a molecule of much interest for 
implantable sensor development. Each 500 µm thick hydrogel slab was tested in a side-
bi-side diffusion cell (PermeGear, Bethlehem, PA) with glucose solution in the donor 
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chamber and deionized water in the receptor chamber, as shown in Figure 4.6. The 
solutions were stirred to sustain constant concentrations throughout the chambers and a 
water jacket was used to maintain a consistent temperature in the system. Samples were 
taken every 10 minutes from the receptor chamber. The glucose concentration was 
measured using a glucose (HK) assay and the absorbance at 340 nm was determined 
with a spectrophotometer (USB 2000, Ocean Optics, Dunedin, FL). 
 
 
 
Figure 4.6. Side-bi-side diffusion cell setup for measuring analyte transport through the polymer 
materials 
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Analysis using Fick’s second law of diffusion was performed to calculate the diffusion 
coefficients. 
 2
2
x
cD
t
c
∂
∂
=
∂
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where c is the concentration in the hydrogel, t is time, D is the diffusion coefficient, and 
x is distance.22-24  This assumes that the chambers are thoroughly mixed and the 
component concentrations are the same at the gel surface and in the bulk fluid. This can 
be solved to: 
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where Qt is the total amount of solute transferred through the hydrogel until time t, A is 
hydrogel area, C1 is the solute concentration in the donor chamber, and l is hydrogel 
thickness. The lag time method has been previously used to calculate the diffusion 
coefficient using the intercept of the linear part of the curve obtained by plotting Q vs. 
time.23 Zhang and Furusaki, however, have shown that using the slope leads to a much 
closer estimation of diffusivity and thus this was used for these calculations.25  
 
PEG-based polymers have been previously shown to not significantly limit the transport 
of glucose to an encapsulated sensor26, so if the nanocomposite hydrogels, samples B 
and C, exhibit similar glucose diffusion rates as the PEG hydrogel, sample D, then they 
should be considered acceptable. Table 4.2 shows that the diffusion rates in the pure 
PNIPAAm hydrogel, A, and the nanocomposite hydrogel, B, decrease significantly 
when the temperature was raised to 37 °C because of the inherent material 
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hydrophobicity and tight mesh size that occur above the VPTT. To overcome this 
potential problem, a porated nanocomposite hydrogel, C, was created. The poration 
caused a significant increase in the diffusion rate, particularly above the VPTT. The 
improvement may be due to the ability of glucose to travel more quickly through the 
pores, as opposed to becoming entrapped within the collapsed hydrogel matrix. 
 
 
Table 4.2. Estimated average diffusion rates at temperatures below and above the volume phase 
transition temperature [cm2/s] 
Material D25 °C D37 °C 
(A) PNIPAAm 0.849 ± 0.24 x 10-6 0.0637 ± 0.04 x 10-6 
(B) Nanocomposite PNIPAAm 1.02 ± 0.33 x 10-6 0.0743 ± 0.01 x 10-6 
(C) Porated Nanocomposite PNIPAAm 1.97 ± 0.29 x 10-6 4.25 ± 0.97 x 10-6 
(D) PEG 1.10 ± 0.23 x 10-6 1.75 ± 0.32 x 10-6 
 
 
 
Cell Release 
To determine if the swelling/deswelling behavior affects the cellular adhesion, in vitro 
studies were performed. Each of the hydrogels and a polystyrene control were UV 
sterilized and inoculated with GFP-H2B 3T3 mouse fibroblast cells. Fibroblasts are 
responsible for the establishment, maintenance and repair of the extracellular matrix.93 In 
addition, fibrous tissue capsules are typically composed of collagen and fibroblasts. This 
particular cell line was chosen to mimic a potential implant environment and because 
GFP-labeled chromatin is easy to image. The cells were maintained in DMEM with 10% 
fetal calf serum and antibiotics in an incubator at 37 °C and 5% CO2. The inoculated 
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hydrogels were incubated overnight to allow the cells to attempt to adhere to the material 
surfaces. The samples were then imaged every 20 minutes and the number of cells 
remaining adhered to the surfaces were counted (Nikon Eclipse TE 2000-S). The 
temperature was varied between 37 °C and 25 °C every hour throughout the imaging 
process. 
 
 
 
Figure 4.7. Comparison of attached cells: (A) Modified PNIPAAm nanocomposite hydrogel at initial 
37 °C, (B) Polystyrene control plate at initial 37 °C, Modified PNIPAAm nanocomposite hydrogel 
after the temperature was lowered to 25 °C, and (D) Control at 25 °C 
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Several steps are typically involved in the adhesion of cells to a substrate including 
attachment of cells to a surface, reorganization of cytoskeletal components, formation of 
adhesion plaques, and deposition of an organized extracellular matrix.97 Fluorescence 
images of the adherent cells are shown in Figure 4.7. Brightfield validation showing the 
cell morphology with the fibroblasts attached to the material surface is shown in Figure 
4.8. The polystyrene control material maintained a high level of cell adhesion over the 
course of the experiment while the nanocomposite PNIPAAm material underwent a 
significant decrease in the number of attached cells when the temperature was lowered 
below the VPTT. 
 
 
 
Figure 4.8. Brightfield validation of a control sample at 37 °C showing the cell morphology of the 
fibroblasts attached to the material surface (A) compared to the fluorescence image of the labeled 
nuclei (B) 
 
 
Figure 4.9 shows the relative number of cells that remained adhered to each material 
throughout the thermal cycling process with the initial cell count being used to normalize 
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the following data. While the polystyrene control remained relatively constant over the 
duration of the experiment, the thermoresponsive hydrogels, A, B, and C, displayed a 
significant decrease in cell adhesion after the initial temperature fluctuation and never 
experienced further re-fouling. The PEG hydrogel, D, exhibited an initial decrease in the 
number of attached cells, likely due to its inherent anti-fouling capabilities. The 
relatively higher number of cells adhered to the PEG surfaces compared to those 
attached to the NIPAAm surfaces was due to the lower initial number of cells on the 
PEG, which was then used for normalization. PEG-coated materials have been shown to 
resist cellular adhesion for up to two weeks in vitro, but have been less successful during 
in vivo studies.139 PEG-coated implants were engulfed by fibrous encapsulation four 
weeks after being subcutaneously implanted in mouse tissue, which limits its potential 
for in vivo sensing.140 
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Figure 4.9. Detachment of cells in response to temperature variation for (A) pure PNIPAAm, (B) 
PNIPAAm with nanoparticles, (C) porated PNIPAAm with nanoparticles, (D) 60% PEG, and (E) 
polystyrene control plate 
 
 
Cell spreading on a receptor-mediated surface depends on a delicate interplay of surface 
forces, including van der Waals interactions, electrostatic forces, cell membrane 
elasticity, steric interactions, and receptor-ligand binding interactions. The cell responds 
to the restraints imposed by the surface and makes the decision to recoil or adhere to the 
surface.141 
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Conclusions 
In order for an implanted biosensor to be successful in vivo, it should exhibit long term 
stability and functionality. Therefore, the host response along with potential fibrous 
encapsulation should be minimized. Novel thermoresponsive PNIPAAm nanocomposite 
hydrogels have been created as possible self-cleaning membranes for implantable 
sensors. The volume phase transition of the gels occurred just below body temperature at 
about 33-34 °C, which is biologically relevant. The diffusion of glucose was similar to 
that in a PEG hydrogel below the VPTT, but significantly decreased at temperatures 
above the VPTT. Poration of the nanocomposite hydrogel dramatically improved 
glucose diffusion at temperatures above the VPTT by minimizing the distance that 
analytes must travel through the solid hydrogel network. An in vitro feasibility study 
showed that the nanocomposite hydrogels released approximately 70-80% of the initially 
attached fibroblast cells when the temperature was decreased below the VPTT and never 
experienced any significant reattachment during subsequent heating and cooling cycles. 
These results suggest that nanocomposite PNIPAAm hydrogels have the potential to be 
used as self-cleaning membranes for implantable biosensors. Long term studies are 
necessary to determine if these thermoresponsive nanocomposite hydrogels are capable 
of extending sensor longevity by preventing significant capsule formation in vivo, but its 
active anti-fouling properties make it a likely possibility. 
  
 67
CHAPTER V 
TAILORING THE VPTT 
 
Introduction 
Following the implantation of a biosensor, the host experiences an immune response that 
results in the adhesion of proteins and cells and eventual fibrous encapsulation that will 
limit analyte diffusion and impair sensor performance. A thermoresponsive 
nanocomposite hydrogel based on poly(N-isopropylacrylamide) (PNIPAAm) has been 
developed for use as a self-cleaning sensor membrane to minimize the effects of the host 
response. In the previous chapter, it was demonstrated that these hydrogels can release 
adhered cells upon thermal cycling. However, the volume phase transition temperature 
(VPTT) for the hydrogels is below body temperature, resulting in a gel that is in a 
collapsed state in vivo, which would ultimately limit diffusion of the target analyte (e.g. 
glucose) to the encapsulated sensor. To overcome this diffusion obstacle, the hydrogel 
could be modified by tailoring the monomer ratio and introducing a copolymer to raise 
the temperature at which the maximum transition occurs. In addition to raising the VPTT 
to improve analyte transport efficiency, the material must be designed for optimal 
removal of adhered proteins and cells to control biofouling, while maintaining adequate 
mechanical strength for use in the body. 
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Normal Body Temperature and Thermoregulation 
The normal body temperature of a human depends on many factors such as gender, race, 
activity level, fluid consumption, and time of day. The average core body temperature 
for healthy adult humans at rest in thermoneutral conditions (when the body temperature 
is controlled without shivering or sweating) is about 36.8 ± 0.4 °C.142,143 This internal 
body temperature is maintained within approximately 2 °C despite large variations in 
ambient temperature. Hardy et al. showed that when temperatures were varied from 22 
to 35 °C, subject core temperatures were relatively stable, while skin temperatures 
changed dramatically, especially at lower ambient temperatures.144 The rate at which 
heat is transferred from the surface of the skin to the environment depends on the 
temperature difference between the two and thermal conductivity of the surrounding 
medium.142  
 
At lower ambient temperatures, the peripheral blood flow is reduced and skin 
temperatures are lowered as the body undergoes vasoconstriction to preserve the core 
temperature. If this conservation is not sufficient to maintain the necessary core 
temperature, shivering will ensue. Alternately, when the internal temperature becomes 
too warm, increased cutaneous blood flow and sweating may occur to dissipate the heat. 
In addition, humans take behavioral measures to adjust for uncomfortable temperatures. 
The comfort zone, shown in Figure 5.1 (adapted from Datta), depends on several factors 
such as air temperature, surrounding surface temperature, relative humidity, and air 
 movement.89 Outside of this comfort range, humans tend to adjust 
such as clothing and shelter.
 
 
Figure 5.1. The effects of temperature and relative humidity on human comfort
 
 
 
Site Specific Conditions 
Temperature variation occurs throughout the body because of differing geometry and 
material inhomogeneity.145
close to the surface of the tissue in order to minimize the signal pathlength. Therefore it 
is likely to be strongly influenced by the environmental temperature, as more superficial 
tissues are more affected by imposed thermal stresses than deeper tissues.
through modifications 
 
 An implanted optical sensor would optimally be located 
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 For this 
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particular application, the sensor is designed to be implanted in the subcutaneous tissue 
on the underside of the forearm for ease of accessibility and skin transparency. The inner 
temperature of the forearm has been determined to be 35.5 °C, but this maximum 
temperature was measured at a depth of 4 cm, near the center of the arm.145 At an 
ambient temperature of 23 °C, the forearm surface temperature has been found to range 
from 29.4 °C on the lateral side to 31.4 °C on the ventral surface.147 If implanted just 
under the surface of the skin, the average normal temperature of the sensor would 
probably be several degrees below 35.5 °C. Thus, body temperature at the implant site is 
considered to be approximately 35 °C in this work. 
 
Choice of Volume Phase Transition Temperature 
In order to induce the “self-cleaning” mechanism of the hydrogel sensor membrane, the 
temperature must be cycled around the VPTT. Because diffusion is limited at 
temperatures above the VPTT, the final hydrogel formulation was designed such that the 
VPTT is just above body temperature. Thus, under normal conditions, the hydrogel 
exists in a swollen state that allows adequate diffusion of the target analyte to the sensor. 
The “self-cleaning” is activated when the local temperature is raised just above the 
VPTT. This temperature must be tightly controlled as a critical thermal maximum exists 
from about 41.6 to 42 °C, beyond which near-lethal or lethal injury may occur.148 The 
choice of temperature range was made to allow for adequate diffusion without incurring 
thermal damage.  
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Potential Thermal Limitations 
As previously stated, the local forearm temperature under thermoneutral conditions is 
typically maintained several degrees below the core temperature. At environmental 
temperatures approaching body temperature, however, the thermal gradient between the 
core and surface temperatures is minimal, as vasodilation ensues to dissipate heat 
through the skin.149 This condition is unlikely to affect the functionality of the sensor 
system as ambient temperatures far outside of the thermal comfort range are typically 
avoided or at very least, minimized. Many communities have public health warnings and 
response systems that are activated in the event of critical weather situations. For 
example, if temperatures are forecasted to be above 32.2 °C for 3 consecutive days, the 
city of Boston opens community cooling centers.150  
 
There are several other case scenarios in which the body temperature may be elevated, 
though. Exercise, especially when performed by untrained individuals in high ambient 
temperatures, can produce high levels of heat and fatigue.151,152 The magnitude of the 
rise in body temperature depends on the intensity of the exercise and is largely 
independent of the environmental temperature.142,153 In a study by Gonzáles-Alonso et 
al., cyclists exercised to hyperthermic fatigue experienced core temperatures of about 
40.2 °C, while their skin temperatures were maintained at less than 37.2 °C.152 As this 
temperature is lower than the VPTT of the proposed sensor implant, normal levels of 
exercise may have little effect on sensor operation. If the sensor system is affected 
during periods of intense exercise, the most likely outcome would be reduced analyte 
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diffusion owing to the deswelling of the hydrogel at temperatures above the VPTT. This 
could be avoided by incorporating a calibration for temperature. As long as the duration 
of the thermal elevation is relatively short, it should not have a significant effect on the 
“self-cleaning” properties. 
 
One other case scenario that may arise is fever. The febrile response typically increases 
the body temperature from 0.5 to 3°C.142 During the course of the fever, the sensor 
hydrogel could remain in the collapsed state. If this occurs for an extended period of 
time, there may be a temporary build-up of cells around the sensor, causing a need for 
recalibration. 
 
Other Considerations 
Because this particular sensor is intended for use in diabetic patients, there may be 
several other factors to consider. One of the potential complications of diabetes involves 
complications with vascular disease. The vascular responses of diabetic patients are 
significantly reduced compared to non-diabetic subjects.154,155 Additionally, glucose has 
a vasoconstricting effect, while insulin promotes vasodilation.156,157 The potential effects 
of these factors on the system could be investigated in the future. 
 
Material Design 
In order to promote maximum diffusion in the hydrogel “resting state”, a 
thermoresponsive material was designed to have a VPTT slightly above body 
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temperature. Several methods are commonly used to alter the VPTT, including adjusting 
the pH or adding surfactants, both of which would be physiologically infeasible.158,159 
The other widely used technique is the introduction of a comonomer.160-162  
 
One of the most extensively used hydrophilic comonomers is acrylic acid (AAc).160-165 
PNIPAAm-co-AAc has been shown to have a higher water content than plain PNIPAAm 
above the VPTT and demonstrates a smaller change in volume.162 In order to increase 
the VPTT to slightly above body temperature, acrylic acid was included into the 
PNIPAAm precursor solution. After optimizing for swelling, diffusion, and strength, the 
formulas were determined as follows: (A) PNIPAAm aqueous solution was composed of 
12.5 wt% NIPAAm monomer, .2wt% BIS cross-linker, 1 wt% Irgacure-2959 
photoinitiator, and 1 wt% polysiloxane colloidal nanoparticles, based on total precursor 
solution weight. (B) Acrylic acid comonomer was substituted for 10 wt% of the total 
monomer composition. The swelling profile for each of these can be seen in Figure 5.2. 
 
 74
 
Figure 5.2. The equilibrium swelling profile with regards to temperature for PNIPAAm hydrogels 
with and without acrylic acid 
 
 
The addition of acrylic acid increases the VPTT, but the transition broadens significantly 
compared to the hydrogels without the comonomer. A less gradual change in swelling is 
more desirable to achieve maximum self-cleaning potential with a small temperature 
change. Another concern is the highly pH sensitive nature of acrylic acid. Though the 
body closely regulates acidity, the local environment around a wound healing site can 
experience minor fluctuations. 
 
In order to raise the VPTT while maintaining a sharper swelling transition, a hydrophilic 
comonomer, N-vinylpyrrolidone (NVP), was added to the PNIPAAm precursor solution. 
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In addition to the main design constraint of the transition temperature, the other 
components of the hydrogel were also considered with regard to impact on swelling, 
diffusion, and mechanical strength. Monomer concentration has a large influence on 
swelling ratio. Typically, the more “solids” included in the hydrogel composition, the 
lower the total degree of swelling. The cross-linker affects the hydrogel structure and 
elasticity. Additional cross-linker agent increases cross-linking and strength while 
decreasing diffusion and the maximum degree of swelling. Kuckling et al. showed that 
low BIS cross-linker contents (1 and 2 mol %) created homogeneous and transparent 
gels, while higher levels of cross-linker created cloudy (4 and 6 mol %) and opaque (8 
and 10 mol %), heterogeneous hydrogels.166 A design of experiments (DOE) analysis 
was performed using JMP statistical software to optimize the formula by varying the 
hydrogel components as described in Table 5.1. 
 
 
Table 5.1. The compositions were varied by altering the percentage of three components 
Component Range 
Total Monomer 10-15 wt% 
NVP 1-2 wt% 
BIS 0.2-1 wt% 
 
 
Each potential combination of components was analyzed base on maximum swelling 
ratio, diffusion, and mechanical strength to predict the most desirable formula for use in 
 the temperature range of interest. Figure 5.3 shows the prediction pro
results of a set of 16 predetermined hydrogel compositions measured in triplicate.
 
 
Figure 5.3. JMP statistical analysis to determine maximum desirability of swelling ratio, diffusion, 
and strength based on total monomer, comonomer, an
 
 
As hypothesized, higher total monomer concentrations and higher cross
led to decreased diffusion, while increasing the amount of hydrophilic NVP led to 
increased diffusion due to the additional hydration of th
increasing the comonomer concentration led to a decrease in strength, while adding more 
cross-linker strengthened the gels. Finally, the swelling ratio, which takes into 
consideration the change in volume between 35 and 39 
concentrations of each of the components. Taking each of these properties into 
file based on the 
d cross-linker concentrations
-linker amounts 
e hydrogels. Conversely, 
°C, was maximized at low 
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consideration, the optimal composition was determined to be 9 wt% NIPAAm monomer, 
1 wt% NVP comonomer, 87.8 wt% water, 0.2 wt% BIS cross-linker, 1 wt% 
nanoparticles (wt % solids of nanoparticles with respect to total precursor solution wt), 
and 1 wt% Irgacure photoinitiator. 
 
Material Characteristics 
The end goal of the design of this material is to prevent long term cell adhesion via 
changes in surface swelling and hydrophobicity. The hydrogel composition was 
optimized such that it will exhibit large changes in hydration between body temperature 
and a slightly elevated “activated” temperature. In order to view the morphological 
differences between the swollen and deswollen states, the hydrogel samples were 
maintained in PBS at either 4 °C or 50 °C for at least 24 hours to promote swelling or 
contraction. They were then flash frozen in liquid N2 to maintain morphology and 
freeze-dried in a lyophilizer (Labconco CentriVap Gel Dryer System, Kansas City, MO) 
for 6 hours at -40 °C to completely remove any water from the hydrogels and preserve 
hydrogel structure and volume.167,168 Cross-sections were sputter-coated with gold and 
visualized with a field emission scanning electron microscope (Quanta 600 FE-SEM, 
FEI, Hillsboro, OR; FE-SEM acquisition was supported by the NSF DBI-0116835, the 
VP for Research Office, and the Texas Engineering Experiment Station). Figure 5.4 
shows that the hydrogels that were maintained in a swollen state below the VPTT 
exhibited a homogeneous, expanded network, while those that were maintained in a 
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deswollen state above the VPTT were homogeneous, but had a much more contracted 
mesh. 
 
 
 
Figure 5.4. SEM micrographs of hydrogels displaying A) swollen morphology after conditioning 
below the VPTT at 4 °C and B) collapsed morphology after conditioning above the VPTT at 50 °C 
 
 
Internal Environment 
Both the external and internal environments must be considered for optimal design 
creation. Characterization of the VPTT of PNIPAAm hydrogels is typically conducted in 
DI water, but it is important to analyze the functionality of an implantable sensor under 
physiological conditions, particularly with respect to pH and salinity. Designed to be 
implanted in the subcutaneous tissue, the sensor will be bathed in interstitial fluid. The 
human body can control the pH of blood and interstitial fluid to within a tenth of a pH 
unit of 7.4.169 Since the pH of DI water is about 7, a slightly more basic solution should 
be used for more accurate testing. PNIPAAm has been considered a slightly pH sensitive 
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material.170,171 However, other work supports the idea that the changes seen are in fact 
due to other factors such as a copolymer or the salts used in the preparation of the pH 
buffer solutions, and not necessarily to the change in pH.158,172 
 
The VPTT of PNIPAAm can be changed with the addition of various salts via a salting 
out effect that causes a decrease in the transition temperature.158,159,173,174 The type of 
salt, valence, size of the anions, and the concentration have a strong influence on the 
effect. The salting out may be due to a combination of several effects, including changes 
of the water structure in the hydration layer surrounding the polymer and changes of the 
interactions between the polymer and the solvent. The addition of electrolytes changes 
the normal hydrogen bonded water structure, disrupting the highly oriented water 
molecules, resulting in an increase in the hydrophobicity of the PNIPAAm and a 
subsequent decrease in the VPTT.159 
 
 
Table 5.2. VPTT of the hydrogels with and without the comonomer NVP in either water or PBS 
 To [°C] Tmax [°C] 
(A) With NVP, in PBS 34.59 ± 0.69 37.44 ± 1.52 
(B) With NVP, in water 38.08 ± 0.25 41.82 ± 0.12 
(C) Without NVP, in PBS 30.38 ± 1.84 31.74 ±1.72 
(D) Without NVP, in water 32.79 ± 0.26 34.85 ± 0.12 
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Given the known effect of pH, salts, and electrolytes on the VPTT of PNIPAAm, studies 
were conducted on nanocomposite hydrogel samples soaked in both DI water as well as 
phosphate buffered saline (PBS). The impact of PBS can be seen in Table 5.2 as 
hydrogels saturated in PBS displayed a lower VPTT in terms of onset (To) and 
maximum (Tmax) temperatures of the endothermic peaks. The volume phase transition 
temperature (VPTT) of the hydrogels was determined using differential scanning 
calorimetry (DSC, TA Instruments Q100, New Castle, DE). After soaking in either DI 
water or PBS at room temperature for at least 24 hours to equilibrate, the hydrogels were 
blotted with filter paper to remove the excess liquid and sealed in a hermetic pan. The 
temperature was cycled between -50 °C and 50 °C at a rate of 3 °C/min with the reported 
data occurring in the 2nd cycle. In addition to the effects seen in the presence of PBS, the 
inclusion of the comonomer also has a large impact on the VPTT. The hydrogels that 
incorporate NVP exhibit higher transition temperatures. Thus, the hydrogels will exist in 
a hydrated, swollen state with increased diffusion at body temperature when implanted 
in the body. 
 
Equilibrium Swelling 
The extent of swelling and deswelling of the hydrogels were determined via equilibrium 
swelling measurements from 10 to 50 °C in both water and in PBS with a pH of 7.4 in 
order to simulate the internal environment of the implantable sensor. The hydrogel slabs 
were submerged in either solution at a specific temperature for 24 hours and then the wet 
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weight (wwet) was measured. The dry weight (wdry) was measured after the hydrogels had 
been dehydrated in an oven at 40 °C for 24 hours. The swelling ratio is defined as: 
 
dry
drywet
w
ww
SR
−
=
 
As seen in the previous DSC measurements of VPTT, Figure 5.5 shows that the VPTT 
occurred at slightly lower temperature for hydrogels soaked in PBS, whereas the 
presence of NVP increased the VPTT due to its hydrophilic nature. Upon implantation, 
swelling of the hydrogel membrane would enhance diffusion in the resting state at 35 °C. 
At ~39 °C in PBS, the hydrogel containing NVP produced the most significant 
deswollen state. The large extent of deswelling in the range between body temperature 
and the “activated” temperature is expected to maximize the self-cleaning mechanism, 
presumably increasing the likelihood of cell detachment upon temperature cycling. 
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Figure 5.5. Equilibrium swelling ratios as a function of temperature for the hydrogels in PBS (A), 
hydrogels in water (B), hydrogels without the NVP comonomer in PBS (C), and hydrogels without 
NVP in water (D) 
 
 
Swelling and Deswelling Kinetics 
Deswelling and swelling kinetics were examined by measuring the change in hydrogel 
diameter at regular time intervals while sequentially heating or cooling hydrogel discs 
from 35 °C (below the VPTT) to 39 °C (above the VPTT). Hydrogel discs were created 
with an 8 mm punch at room temperature. The samples were submerged in PBS at either 
35 or 39 °C for 24 hours to equilibrate and then switched to the opposite temperature at 
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time zero. The diameter was measured over time using a digital caliper. Whereas 
swelling began rapidly upon cooling, deswelling appeared to be slower, as shown in 
Figure 5.6. This may be due in part to the limitations of the measurement process. The 
diameters of the hydrogels during deswelling may have increased during the physical 
measurement at room temperature due to reswelling even though each measurement 
lasted only a few seconds. Also, as pointed out in the previous chapter, the surface of the 
hydrogel may immediately deswell, effectively forming a skin that inhibits the transport 
of water from the center of the gels.119,175 Enhanced deswelling may be effected with 
methods such as modification of the polymerization conditions, poration, and freeze-
drying that may be useful if a quicker transition is necessary.168,176-178 
 
 
 
Figure 5.6. Phase transition over time showing swelling upon cooling to 35 °C and deswelling when 
the hydrogels were heated to 39 °C 
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Glucose Diffusion 
The diffusion through the hydrogels was studied using glucose as an example analyte. A 
side-bi-side diffusion cell was used to monitor the glucose transport through the gels. 
The donor chamber was filled with glucose solution and the receptor chamber contained 
DI water at the beginning of the experiment. The solutions were stirred to provide even 
analyte distribution and a water jacket was used to maintain a consistent temperature. 
Samples were taken every 20 minutes from the receptor chamber and the glucose 
concentration was measured using a YSI 2700 Select Biochemistry Analyzer (YSI 
Incorporated, Yellow Springs, OH). The average thickness of each of the gels was 
measured with a DMA Q800 (TA Instruments, New Castle, DE) and the diffusion 
coefficients were calculated for each case using Fick’s second law of diffusion, as 
outlined previously in Chapter IV. 
 
Table 5.3 shows the effect of temperature on the diffusion coefficients of hydrogels that 
were created with and without the comonomer NVP. Without the addition of NVP, the 
diffusion rate decreases significantly with temperature. If it were to be implanted in the 
body, the diffusion rate could be prohibitive when the external heating device is 
activated to promote cleaning of the hydrogel surface. By including NVP in the 
hydrogels, the diffusion rate is significantly improved at the temperatures of interest. 
Glucose diffusion through the dermal layer of skin has been previously measured as 2.64 
x 10-6 cm2/s and as 0.075 x 10-6 cm2/s through the epidermis.49 Furthermore, Sharkawy 
et al. have shown that densely fibrous, avascular tissues forming around implanted 
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materials reduce diffusion by 50% compared to rates measured in the subcutis, 
potentially increasing the sensor lag time by threefold.107 Though the NVP-inclusive 
hydrogels experience a slight decrease in diffusion rate at the activated temperature, their 
self-cleaning properties may provide significant improvement of long-term diffusion 
rates in vivo. 
 
 
Table 5.3. The effect of temperature on diffusion coefficients of hydrogels with and without the 
comonomer NVP [cm2/s] 
Temperature [°C] Without NVP With NVP 
30 1.09 ± 0.39 x 10-6 1.33 ± 0.18 x 10-6 
35 0.193 ± 0.06 x 10-6 1.24 ± 0.15 x 10-6 
39 0.0483 ± 0.01 x 10-6 0.785 ± 0.30 x 10-6 
 
 
 
Mechanical Properties 
Mechanical robustness is desired for an implanted sensor membrane to permit easy 
insertion and removal, as well as promote integrity during residence in the body. 
Although swelling enhances diffusion, it also leads to reduced mechanical strength. The 
high water content typical of hydrogels increases flexibility, minimizing the local tissue 
irritation that could occur with a stiffer material, but can also contribute to reduced 
mechanical integrity.131 The mechanical properties of an implant are typically designed 
to match that of the local environment. In the case of a subcutaneous implant that is not 
load-bearing, the main physical requirements are that the implant be able to maintain its 
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functionality throughout its useful lifetime and then be able to be fully removed. Many 
methods for improving hydrogel strength do so by reducing the extent of swelling.179 For 
instance, PNIPAAm hydrogels formed at temperatures below 20 °C are morphologically 
homogeneous whereas those formed at higher temperatures are heterogeneous.180-183 At 
temperatures above ~ 20 °C, newly formed insoluble PNIPAAm chains phase separate 
such that subsequent cross-linking leads to the formation of a macroscopic network of 
loosely interconnected highly cross-linked polymer rich domains and lightly cross-linked 
polymer poor domains. Heterogeneous PNIPAAm hydrogels display greater swelling 
but are mechanically weaker compared to the corresponding homogeneous hydrogel. To 
maintain mechanical integrity, homogeneous hydrogels were prepared for this study.  
Furthermore, polysiloxane colloidal nanoparticles have been incorporated to improve the 
mechanical properties of the nanocomposite hydrogels without affecting the volume 
phase transition temperature.134 For compression and tensile tests, measures were taken 
to avoid dehydration of the specimens that would falsely increase mechanical rigidity 
and strength. 
 
In order to assess the effects of temperature on the mechanical properties of the 
nanocomposite hydrogels, dynamic mechanical analysis (DMA) and tensile testing was 
performed at 35 °C (below the VPTT) and at 39 °C (above the VPTT). DMA was 
performed in the compression mode using a DMA Q800 (TA Instruments, New Castle, 
DE) equipped with a parallel-plate compression clamp with a bottom diameter of 40 mm 
and a top diameter of 15 mm. Hydrogel discs were prepared with a diameter of 13 mm 
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using a punch, clamped between the parallel plates, and silicone oil was placed around 
the exposed edges to prevent dehydration during the testing process. The hydrogel discs 
were allowed to equilibrate for 5 minutes at 25 °C and then were evaluated in multi-
frequency-strain mode (1 to 100 Hz). 
 
Analysis of tensile strength was performed using a DMA Q800 operating in tension 
mode. Specimens with a ring geometry were prepared using a tubular mold (ID = 3 mm, 
OD = 7.5 mm). Individual rings of ~3 mm width were cut from the central portion of the 
appropriate hydrogel tube using a clean razor blade and sample dimensions were 
measured using a digital caliper. Each hydrogel ring was blotted with filter paper and 
loaded onto the outside of custom aluminum bars that were fixed in the DMA tension 
clamps so that the upper and lower bars were located inside the ring. The hydrogels were 
subjected to a constant strain (1 mm/min) until breaking at the center of one side of the 
ring. Stress was determined using the measured force divided by the cross-sectional area 
of two rectangles with dimensions based on the ring width and wall thickness. The 
tensile modulus, ultimate tensile strength (UTS) and % strain at break were determined. 
The tensile modulus was obtained from the slope of the linear part of the stress-strain 
curve. The UTS was designated as the maximum stress prior to failure. Percent strain at 
break was calculated by dividing the measured displacement by the gauge length, which 
was found by subtracting the ring wall thickness from the outer diameter. Results 
reported are the average of measurements from three specimens cut from the central 
portion of the same hydrogel tube. 
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Figure 5.7. Storage modulus of the nanocomposite PNIPAAm-co-NVP hydrogels at 35 and 39 °C 
measured in compression mode 
 
 
In DMA, the storage modulus, G’, is related to the stiffness or rigidity of the material.184 
Figure 5.7 shows the relationship between G’ and temperature for the nanocomposite 
hydrogels. As expected, the deswollen hydrogels at 39 °C exhibited a higher G’ at all 
frequencies compared to the swollen hydrogels at 35 °C due to the lower water content 
of the former samples. The tensile modulus, ultimate tensile strength (UTS), and percent 
strain at break also increased for the deswollen hydrogel, as shown in Table 5.4. The 
constantly changing hydrogel stiffness between the resting and activated temperatures 
may contribute to cell detachment upon thermal cycling. Materials with modulus values 
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much greater than the surrounding tissue are known to cause local irritation and an 
increased host response. Though the mechanical properties of specialized connective 
tissue such as bone, cartilage, and tendon have been extensively studied, much less 
information is available regarding the behavior of loose connective tissue in humans. 
Iatridis et al. determined that the equilibrium tensile modulus of subcutaneous rat tissue 
is approximately 2.75 kPa.185 Thus, the modulus of the hydrogel in the deswollen as well 
as the swollen state are similar to soft tissue and would be expected to minimize local 
tissue irritation. 
 
 
Table 5.4. Tensile properties of the hydrogels 
 35 °C 39 °C 
Modulus [kPa] 2.0 ± 0.4 8.5 ± 1.1 
UTS [kPa] 89.2 ± 27.9 353.7 ± 46.2 
% strain at break 68.3 ± 7.1 78.8 ± 5.8 
 
 
Self-Cleaning via Cell Release  
The effects of a variable thermal environment on cell adhesion were studied using GFP-
labeled H2B 3T3 mouse fibroblast cells. Hydrogels and polystyrene controls were 
sterilized by exposure to 70% ethanol for 45 minutes. The samples were then washed 
three times with sterile Dulbecco’s PBS for 30 minutes each and placed in DMEM 
overnight. The samples were inoculated with GFP-H2B 3T3 mouse fibroblast cells 
maintained in DMEM with 10% fetal calf serum and antibiotics. The samples were then 
randomly assigned to one of two groups. The control group was maintained at a constant 
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temperature of 35 °C while the variable group was cycled between 35 and 39 °C every 
hour. Samples of each material and group were removed daily and imaged (Nikon 
Eclipse TE 2000-S) to obtain an average cell count. 
 
 
 
Figure 5.8. Cell adhesion over time for hydrogels and controls maintained at either constant or 
variable temperatures 
 
 
Figure 5.8 shows that in the constant temperature group, the number of cells increased 
throughout the week. The control samples have more cell attachment at the end of the 
week than the gels, potentially due to the hydrogels remaining in a relatively hydrophilic 
state while cells tend to grow well on more hydrophobic surfaces. The control specimens 
that experienced variable temperatures exhibited increasing cell numbers over time, 
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showing that implementing thermal cycling by this protocol does not destroy cells. The 
slight decrease in cell count between days 5 and 6 is attributed to cells that may have 
been disturbed when the used cell culture media was exchanged for fresh DMEM. The 
“activated” time required to completely detach cells from PNIPAAm films depends on 
cell types and physiochemical properties of the specific hydrogel.186 The hydrogels that 
were subject to thermal cycling showed very little cell adhesion over the duration of the 
study, demonstrating the possibility of using this system to promote self-cleaning of an 
implantable sensor. 
 
Conclusions 
In an effort to design an implant material that can overcome the host response to a 
foreign body while maintaining sufficient levels of analyte diffusion and mechanical 
strength, the composition of a PNIPAAm-based thermoresponsive nanocomposite 
hydrogel was optimized for in vivo conditions. During the design process, the site 
specific environment including factors such as local temperature and salinity were 
considered, and JMP statistical analysis was used to create the optimal formulation. By 
incorporating a hydrophilic comonomer, NVP, the volume phase transition temperature 
was raised such that at body temperature the hydrogel exists in the swollen state, thus 
permitting increased glucose diffusion through the hydrogel to the enclosed sensor. The 
“self-cleaning” mechanism of the hydrogel membrane is activated by cyclically raising 
the temperature above the VPTT and subsequently cooling to body temperature. Even 
though the diffusion rate is slightly lower in the “active” state, the addition of NVP 
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significantly improves glucose transfer. During deswelling, the dynamic compression 
modulus, G’, as well as tensile modulus increased. This increase in hydrogel rigidity 
should contribute to diminished adhesion of cells as well as the change in surface 
hydrophilicity during thermal cycling. Over a period of 7 days, it was found that 
thermally cycled hydrogels experienced very low levels of cell attachment throughout 
the course of the study. Though further research is needed to determine the necessary 
duty cycle to promote optimal diffusion while limiting cell adhesion and to assess in vivo 
functionality, the in vitro cell adhesion rates are promising.  
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CHAPTER VI 
SENSOR IMPLANT IMPLEMENTATION 
 
Sensing System 
In order to take a glucose-sensitive assay from a cuvette to the body, thorough design 
must occur, taking into consideration all of the normal site specific conditions and 
possibilities for problems. Implementing the self-cleaning membrane discussed in the 
previous chapters involves the introduction of an internal component to sense glucose in 
the interstitial fluid as well as an external device to measure the fluorescence signal and 
regulate the hydrogel temperature. Figure 6.1 shows the schematic of the proposed 
system. The interface device is relatively simple, with a large LCD screen and only three 
buttons, keeping in mind the aging target population. Stylistically, the device is a cross 
between a watch and a glucometer, promoting discretion and potentially increasing 
patient use in public. Additionally, the size has been minimized for comfort and 
portability. Typical outer dimensions of a wrist-wearable medical device are about 60 x 
50 x 15 mm.187 In order to house the multitude of components, mechanical and electrical 
codesign is necessary throughout the development phase. High-density packaging (HDP) 
and 3D integration (3DI) technologies may be useful for creating highly integrated 
nanochips with high speeds and miniscule dimensions.188,189 The housing of the  device 
should render it shockproof, conforming to IP 65 class according to IEC 60529, Degrees 
of Protection Provided by Enclosures.187 Additionally, the interface between the patient 
and the device must be biocompatible. While the implant may need to be replaced on a 
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regular basis, the external device should have a field life of approximately four years in 
order to be eligible for reimbursement by many health insurance companies.187 
 
 
 
Figure 6.1. Schematic of the proposed system with optics for analyte detection and a heating element 
for activating “self-cleaning” of the implant 
 
 
The underside of the device contains an optical system, comprised of an LED and 
photodetector, as well as a heating element, all of which should ideally be low-power to 
extend battery life and increase safety. The heating element is transparent to allow for 
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light transmission to and from the optical components (Thermal-clear transparent heater, 
Minco, Minneapolis, MN). Clear, flexible heaters were developed for military 
applications such as laser sights, cockpit displays, and pilot helmets, specifically because 
LCD screens do not function well at low temperatures.190 They are useful for this 
application because they can simultaneously occupy the same space as the optical 
devices, minimizing the size of the system and the affected skin surface area. 
Additionally, the flexibility of the heaters allows the device to fit snugly against the 
forearm for maximum heat conduction. 
 
One potential concern for a system such as this is cost. While the initial implantation and 
upfront fee for the device may be more expensive than the average glucometer, there are 
no disposable components such as test strips that need to be purchased for each test. 
Also, by providing the potential for increased glycemic control, overall health expenses 
may decrease as long-term complications are minimized. The annual cost difference 
between well-monitored and poorly monitored diabetic patients is about €2000 (~$2800) 
per year.187 
 
Heat Propagation 
In order to determine the effects of heating at the skin surface to raise the implanted 
hydrogel above the VPTT and trigger the self-cleaning response, it is useful to model the 
temperature distribution throughout the system. Figure 6.2 shows the tissue geometry in 
one dimension beginning with the epidermis at the surface and progressing through the 
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highly vascularized dermis and into the fatty subcutaneous tissue. Heat may be produced 
by the heater at the surface as well as by the metabolic processes of the body. If the 
sensor is inserted just below the epidermis, the heat only has to travel through one 80 μm 
layer to activate the self-cleaning of the hydrogel sensor. 
 
 
 
Figure 6.2. Model of one-dimensional tissue geometry 
 
 
From a thermal point of view, biological systems consist of a different tissue layers and 
a complex network of blood vessels that distribute heat through the surrounding media. 
The temperature distributions within each tissue layer can be derived using the bioheat 
transfer equation. 
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where ρ, ρb are densities of tissue and blood in kg/m3, c, cb are the specific heats of tissue 
and blood in J/kg·K, T, Tb are the temperatures of tissue and blood in K, t is time, k is the 
heat conductivity of tissue in W/m·K, ωb is the flow rate of blood in m3/m3·sec, and Q is 
the metabolic rate in J/m3·sec.89,191 The thermal properties of each of the skin 
components can be seen in Table 6.1.192 
 
 
Table 6.1. Thermal properties of skin tissue components 
Component k (W/m∙K) ρ[kg/m3] c [J/kg∙K] 
Epidermis 0.34 1,120 3,200 
Dermis 0.41 1,090 3,500 
Blood 0.55 1,060 3,600 
 
 
The arterial blood temperature measured at the distal portion of the brachial artery in the 
forearm is about 36.63 °C and blood flow was found to be 6.2 ml/min∙100 ml tissue, 
which is approximately 0.00103 m3/m3∙sec.193 The density of the hydrogel sensor is 
1,032 kg/m3 and the specific heat is around 8,500 J/kg∙K.194,195 Figure 6.3 shows the 
thermal profile as heat is applied to the surface of the epidermis. The heat travels quickly 
through the thin epidermal layer, while the highly vascularized dermis tends to remain 
closer to the core body temperature. 
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Figure 6.3. Thermal profile as heat is applied 
 
 
Ice application with compression has been shown to have a greater rate of cooling than 
treatment without compression.196 This may be applicable for the implementation of this 
device as compression may be applied by the watchband, aiding conduction and 
reducing the amount of time that the heater must be activated, thereby prolonging battery 
life. 
 
Light Propagation 
Light must also propagate through the tissue to reach the sensor. Skin properties can 
vary widely from person to person depending on genetics and environment. Pigments 
such as melanin, oxyhemoglobin, deoxyhemoglobin, carotenoids, and bilirubin are 
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involved in producing skin color.197,198 Most biological tissues are strongly scattering or 
turbid, but optical absorption is relatively weak in the range of about 650 to 1300 nm, 
which is called the optical or therapeutic window.199 Figure 6.4 shows the increased 
levels of absorption at wavelengths below the optical window due to tissue constituents 
such as protein, melanin, and hemoglobin. Water is one of the primary absorbers at 
wavelengths above the optical window, along with collagen at higher wavlenghts.200 In 
the key optical window range, the typical absorption coefficient is about 0.1 to 1 cm-1, 
which means that a photon can travel from 1 to 10 cm before it is absorbed.201 Heating 
causes an increase in cutaneous blood flow and vasodilation, while cooling causes 
vasoconstriction and closing of capillary shunts. Because light scattering by human skin 
is linearly dependent on temperature, the optical signal may need to be calibrated at both 
body temperature and the elevated activated temperature.202  
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Figure 6.4. Absorption spectra of several main tissue components 
 
 
Photon migration in a biological tissue such as skin can be numerically simulated using 
the Monte Carlo method.203 The trajectory of each photon is modeled as a persistent 
random walk in which the direction of the step is dependent on the previous step. At 
boundaries, a photon is either reflected or passes across the boundary. Monte Carlo 
calculates probability distributions for each type of interaction (scattering or absorption), 
randomly sampling variables, and as the name implies, is like throwing the dice. 
 
The optical properties and thickness of the skin and sensor layers used in the modeling 
are shown in Table 6.2.204-209 Each layer is treated as a flat, homogenous material with a 
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semi-infinite geometry compared to that of the beam size. The original Monte Carlo 
code was generated by Mark A. Mackanos of VaNTH and modified by Alex Abraham. 
 
 
Table 6.2. Optical properties of skin model layers 
Layer Thickness 
[μm] 
  n μa [mm
-1
] μs [mm
-1
] 
488 nm 
μs [mm
-1
] 
700 nm 
g 
Stratum corneum 10 1.50 0.2 40 20 0.9 
Epidermis 80 1.34 0.15 35 10 0.85 
Sensor layer 1000 1.508 0.1 35 28 0.6 
Papillary dermis 100 1.40 0.7 30 12 0.8 
Upper blood net dermis 80 1.39 1.0 35 15 0.9 
Dermis 1500 1.40 0.7 27 12 0.76 
Deep blood net dermis 200 1.39 1.0 35 15 0.95 
Subcutaneous fat 5000 1.44 0.3 15 5 0.8 
 
 
Theoretically, the implanted sensor would be as small as possible to enable easy delivery 
and minimal tissue disruption. However, Figure 6.5 shows the correlation between 
sensor thickness and signal intensity. As the sensor size is minimized, the emission also 
decreases as there is less area for fluorophore to interact with the light. One potential 
way to improve the signal would be to use a higher excitation power, but there are 
tradeoffs with battery life. Also, the current regulations set by the American National 
Standard for Safe Use of Lasers (ANSI Z136.1) limit the maximum permissible 
exposure limits in terms of power and time, depending on the chosen light source. For 
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example, when using a continuous wave HeNe laser, 2.5 x 10-3 W/cm2 is permissible for 
0.25 seconds, while only 293 x 10-6 W/cm2 is allowed for a duration of 600 seconds.210 
Another method to potentially increase the intensity of the signal is to increase the assay 
concentration. There is an optimal amount of fluorophore for tagging the assay, above 
which, quenching or a decrease in the dynamic range may be experienced. However, 
high quantities of the labeled assay could be introduced to the sensor implant, provided 
that there is still enough room for sufficient binding and unbinding motility. The 
detection process is reversible and does not consume the analyte so an increase in assay 
should not be physiologically problematic. 
 
 
 
Figure 6.5. Dependence of signal intensity on excitation power and sensor thickness 
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Another factor to consider is implant depth. The sensor must be located below the 
epidermis for long term use because the surface of the skin is constantly sloughed off as 
it regenerates. On the other hand, increased depth leads to a significant decrease in signal 
strength, as shown in Figure 6.6. Additionally, the sensor membrane becomes harder to 
heat as the heat must penetrate farther into the tissue and the thermal equilibrating 
effects of the deeper vasculature become more prominent. Ideally, the surface of the 
implant would be located directly under the epidermal layer for optimal optical and 
thermal outcomes. 
 
 
 
Figure 6.6. Relationship between implant depth and signal intensity 
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Sensor Implant 
It can be useful to model a new design after previous cases that have been successful. In 
humans, common implants include microchips, radiation implants, and contraceptives. 
Hormonal contraceptive implants in particular have been widely studied, including 
Norplant, Jadelle, and Implanon, which have been approved for use in Europe, North 
America, and several other countries.211 Each of these implants is comprised of at least 
one cylindrical rod ranging in volume from about 125 mm3 to 211 mm3, as shown in 
Table 6.3. 
 
 
Table 6.3. Physical properties of common contraceptive implants 
 Number of Implants Diameter Length 
Norplant 6 2.4 mm 34 mm 
Jadelle 2 2.5 mm 43 mm 
Implanon 1 2 mm 40 mm 
 
 
The proposed self-cleaning implant will also have a cylindrical rod shape. The form is 
easy to manufacture using a glass mold consisting of a hollow tube with a solid rod in 
the center. After polymerization, the assay is loaded into the center of the implant and 
the ends are capped with additional polymer. Highly angular polymer surfaces have 
shown to induce the highest enzyme activity and cellular response upon implantation.212 
Therefore, even the ends of the hydrogel tubes will be rounded, as shown in Figure 6.7. 
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Figure 6.7. Comparative sizes of implants 
 
 
Another positive aspect to the rod shape design is potential ease of implantation via a 
needle-type injection device. The delivery process would be similar to that of the 
insertion of hormonal contraceptive implants such as Norplant or Implanon.213 The 
applicator device can be seen in Figure 6.8. After cleaning the insertion site with 
antiseptic, a local anesthetic can be applied if needed. The needle tip is inserted just 
under the skin and the obturator is released as the cannula is retracted back along the 
length of the obturator, leaving the sensor in place.214 If necessary, saline could be 
injected first, creating a pocket in the tissue in which to implant the sensing device. 
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In order to remove the implant after the assay is no longer effective, a small incision 
would be made at the tip of the rod. The implant would be manipulated toward the 
incision, grasped with forceps, and gently removed. A new sensor could be inserted 
before the incision is closed. 
 
 
 
Figure 6.8. Applicator device for sensor implantation 
 
 
The insertion and removal process have been described as easy, typically taking less 
than 1 and 4 minutes to achieve, respectively.213 One of the concerns during device 
delivery was accidental non-insertion whereby the rod either remains in the applicator or 
falls out prior to insertion.214 This should be recognized immediately as the fluorescence 
signal would be detected upon implantation. Furthermore, location indicator dyes would 
be incorporated into the end caps of the sensor rod, as shown in Figure 6.1, to distinguish 
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position. If the distance between the locators appears smaller than expected, the rod may 
have been implanted on an angle and needs to be adjusted before use. The average 
removal time is slightly higher than implantation times due to the potential for more 
complications.213 Because the hormonal contraceptive implants are detected through 
palpation, many problems stemmed from difficulty in locating the implant, particularly 
when it was too deeply embedded in the tissue. The presence of the locator indicator 
dyes should prevent this problem. Another issue that was experienced by several patients 
was implant adhesion to underlying tissue accompanied by a thick fibrotic sheath. This 
will hopefully be avoided because of the self-cleaning nature of the hydrogel material. 
The only issue seen in the removal of Implanon that may be problematic is the 
possibility of breakage. The hydrogel would then have to be removed in several pieces 
and the assay solution could be released into the body if it is not embedded in 
microspheres. Though there has been concern about the toxicity of Concanavalin A, 
Ballerstadt et al. have recently shown that small amounts of Con A pose little or no 
health risk in the event of sensor rupture.215 The most likely outcome of a situation in 
which the implant fractured upon removal would be switching the location of the new 
implant to the opposite forearm so as to avoid signal interference with any fluorophore 
temporarily left in the local area. 
 
Regulatory Standards 
In the United States, regulations for medical devices are derived from five principle laws 
that include the Federal Food, Drug and Cosmetic Act of 1938, Medical Device 
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Amendments of 1976, Safe Medical Devices Act of 1990, Medical Device Amendments 
of 1992, and FDA Modernization Act of 1997 (Section 204).216 Devices are classified in 
one of three categories as shown in Table 6.4 and regulation increases with higher class 
number. Most Class I devices are exempt from Premarket Notification 510 (k), but it is 
required for most Class II devices. The majority of Class III devices require a more 
intensive Premarket Approval.217  
 
 
Table 6.4. Classification of medical devices 
Category Description Distribution 
Class I General controls Over-the-counter 
Class II Performance standards and special controls Physician-controlled 
Class III Premarket approval Clinical use only 
 
 
According to the Food and Drug Administration (FDA) product classification database, 
both noninvasive and invasive glucose sensors are currently listed as Class III devices. 
Class III devices are those that support or sustain human life, are of substantial 
importance in preventing impairment of human health, or which present a potential risk. 
Products requiring premarket approval (PMA) are either high risk devices that pose a 
significant risk of illness or injury or are devices found not substantially equivalent to 
approved Class I and II devices.217 The PMA process is the most stringent type of device 
marketing application, requiring sufficient clinical data as evidence to support the claims 
and assure that the device is safe and effective for its intended use. 
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In addition to regulations set by the FDA, standards relating to biomedical materials and 
devices are set by the International Standards Organization (ISO) and the American 
Society for the Testing of Materials (ASTM). These include ISO 10993: Biological 
evaluation of medical devices and F748 issued by the F04 ASTM committee on medical 
and surgical devices and materials.218 These standards provide guidelines for 
performance characteristics and can be used to characterize a device as part of the safety 
review for PMA. 
 
Summary 
In an attempt to translate a glucose-sensitive assay from the research laboratory to 
clinical use, several implementation design concepts were considered. A system design 
was proposed that includes both heating and optical elements for self-cleaning and 
analyte monitoring, respectively. The ideal implant placement for both thermal and 
optical purposes is at minimal tissue depth, but it must be located below the epidermal 
layer for long-term stability. For ease of implantation and minimal local tissue irritation, 
the sensor size should be minimized. However, there is a tradeoff with signal strength. 
This could potentially be overcome by adjusting the excitation power and assay 
concentration. The implant design has been modeled after currently used hormonal 
contraceptive implants. The cylindrical shape allows for easy deliver and removal by a 
trained clinician in a matter of a few minutes. Though the Class III classification of 
glucose-sensing devices requires a stringent PMA process for approval, the numerous 
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laboratory tests that have been and will be conducted on these materials will help ensure 
the safety and efficacy of this device. 
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CHAPTER VII 
 
SUMMARY 
 
Review of Results 
Diabetes is a disease in which the body does not produce or properly use insulin, leading 
to abnormal glucose levels in the body and a significantly increased potential for long-
term complications. Continuous glucose monitoring (CGM) has been shown to increase 
glycemic control in diabetic patients, leading to overall improved health outcomes. 
However, currently available CGM systems are invasive and limited to short-term use 
between 3 and 7 days. Fluorescence-affinity sensing has demonstrated potential for fast, 
reagentless, minimally invasive glucose measurement. The purpose of this research was 
to help advance a glucose-sensitive assay from cuvette to clinical use. To this end, 
several main objectives were identified including improving the assay encapsulation to 
increase sensor response and developing a membrane to prolong sensor implant efficacy 
and lifespan. 
 
Microporation of poly(ethylene glycol) (PEG) spheres was used to create cavities of 
solution in which analytes may freely diffuse and interact with the sensing elements. 
This process allows for the use of a fine hydrogel mesh size to minimize leaching, 
thereby increasing sensor lifetime, without limiting the mobility of the assay components 
to bind and unbind, promoting both functionality and stability of the encapsulated 
sensors. 
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A “self-cleaning” sensor implant membrane was developed with temperature-dependent 
surface hydrophobicity that limits cellular adhesion in response to thermal cycling 
around the volume phase transition temperature (VPTT). However, the original 
nanocomposite PNIPAAm hydrogel formulation had a VPTT around 33-34 °C, resulting 
in a gel that is in a collapsed state at body temperature, limiting diffusion. The VPTT 
was increased by introducing a hydrophilic comonomer, N-vinylpyrrolidone (NVP) and 
the new formulation was optimized with regard to diffusion, mechanical strength, and 
cell releasing capabilities under physiological conditions.  
 
Recommendations 
Several aspects can be considered for future work to continue this research. The 
concepts that make the microporated spheres effective would be improved by the use of 
fully hollow spheres. There have been some advances using layer-by-layer self assembly 
to achieve this, but as of yet, the process appears to be too harsh to retain complete assay 
functionality.  
 
In terms of improving the self-cleaning membrane, various nanoparticle sizes could be 
studied. Smaller particles may lead to increased optical clarity, allowing higher 
concentrations to be used in the precursor solution, thereby increasing the hydrogel 
mechanical strength. Furthermore, testing in PBS showed deviations in performance 
from those observed in DI water. To more closely study potential effects under 
physiological conditions, characterization could be done in interstitial fluid. 
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Additionally, the duty cycle of the heating system could be optimized by studying the 
minimal amount of activated time necessary to promote an effectively clean surface for 
maximum sensor performance while simultaneously allowing sufficient glucose 
transport through the membrane. Finally, cell culture has been used to assess the 
potential of these materials, but in vivo studies are necessary to determine the actual 
performance characteristics needed for long-term use. Though there is much work to be 
done, overall, this system is a promising start in an effort to achieve an effective sensor 
implant for minimally invasive continuous glucose sensing. 
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